

1 **Psychosocial adversity experienced in utero and early life is associated with**
2 **variation in gut microbiota: a prospective case-control study**

3
4 Barbara B. Warner^{1,&,*}, Bruce A. Rosa^{2,&}, I. Malick Ndao¹, Phillip I. Tarr^{1,3}, J. Phillip
5 Miller⁴, Sara K. England⁵ Joan L. Luby⁶, Cynthia E. Rogers⁶, Carla Hall-Moore¹,
6 Renay E. Bryant¹, Jacqueline D. Wang¹, Laura Linneman¹ Tara A. Smyser⁷,
7 Christopher D. Smyser⁷, Deanna M. Barch⁸, Gregory E. Miller⁹ Edith Chen⁹, John
8 Martin² and Makedonka Mitreva^{10*}

9
10 ¹ Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
11 63110

12 ² Department of Medicine, Washington University School of Medicine, St. Louis, MO
13 63110

14 ³ Department of Molecular Microbiology, Washington University School of Medicine, St.
15 Louis, MO 63110

16 ⁴ Division of Biostatistics, Office of Health Information and Data Science, Washington
17 University School of Medicine in St. Louis, St. Louis, MO 63110

18 ⁵ Department of Obstetrics and Gynecology, Washington University in St. Louis, St.
19 Louis, Missouri, 63110

20 ⁶ Department of Psychiatry, Washington University School of Medicine in St. Louis, St.
21 Louis, MO 63110

22 ⁷ Departments of Neurology, Pediatrics and Radiology, Washington University School of
23 Medicine in St. Louis, MO 63110

24 ⁸ Department of Psychological and Brain Sciences, Washington University in St. Louis,
25 St. Louis, MO 63130

26 ⁹ Institute for Policy Research & Department of Psychology, Northwestern University,
27 Evanston, Illinois 60208

28 ¹⁰ Departments of Medicine, Genetics and McDonnell Genome Institute, Washington
29 University School of Medicine in St. Louis, St. Louis, MO 63110

30 * **Correspondence:** Warner BB, warnerbb@wustl.edu; Mitreva M, mmitreva@wustl.edu

31 & **Equal contribution:** Warner BB, warnerbb@wustl.edu; Rosa BA, barosa@wustl.edu

32

33 **Email addresses**

34 Barbara B Warner: warnerbb@wustl.edu

35 Bruce A. Rosa: barosa@wustl.edu

36 I. Malick Ndao: ndao_m@wustl.edu

37 Phillip I. Tarr: tarr@wustl.edu

38 J. Philip Miller: jphilipmiller@wustl.edu

39 Sara K. England: englands@wustl.edu

40 Joan Luby: lubyj@wustl.edu

41 Cynthia Rogers: rogersc@wustl.edu

42 Carla Hall-Moore: cmhall@wustl.edu

43 Renay E. Bryant: renay@wustl.edu

44 Jacqueline D. Wang: jackie.wang@wustl.edu

45 Laura Linneman: linneman@wustl.edu

46 Tara A. Smyser: smysert@wustl.edu

47 Christopher D. Smyser: smyserc@wustl.edu

48 Deanna M. Barch: dbarch@wustl.edu

49 Gregory E. Miller: greg.miller@northwestern.edu

50 Edith Chen: edith.chen@northwestern.edu

51 John Martin: jmartin@wustl.edu

52 Makedonka Mitreva: mmitreva@wustl.edu

53

54 **Keywords:** infant, neonatal, parental, gut microbiome, social disadvantage,
55 psychological stressors, machine learning, predictive modeling

56

57 **Abstract**

58 Social disadvantage (SD) and psychological stressors (PS) trap some populations in
59 poverty, resulting in health inequities. How these two factors become biologically
60 embedded and the pathways leading to adverse health outcomes is unclear, especially
61 in infants exposed to psychosocial adversity in utero and during early life. Variation in gut
62 microbiome structure and functions, and systemic elevations in circulating cytokines
63 levels as indices of inflammation, offer two possible causative pathways. Here, we
64 interrogate the gut microbiome of mother-child dyads and maternal inflammatory markers,
65 and compare high-SD/high-PS dyads to pairs with low-SD/Low-PS, and demonstrate that
66 the GM of high-SD and high-PS mothers may already be compromised, resulting in the
67 lowest observed inter-individual similarity in that group. The strong predictors of maternal
68 high-SD and high-PS based on mothers and children microbiomes were phylogenetically
69 very distinct bacteria indicating different GM pathways associated with SD versus PS.

70 We identified sets of SD- and PS-discriminatory metabolic pathways in the mothers and
71 in the children, however their predictive power was lower compared to the discriminatory
72 bacterial species. Prediction accuracy was consistently greater for IL-6 than for the other
73 inflammatory markers, supporting an association between systemic inflammation and
74 psychosocial adversity. The gut microbiome of the infants can be used to predict
75 the psychosocial adversity of mothers, and are embedded in the gut microbiota of 4-
76 month-old infants.

77

78 **INTRODUCTION**

79 Health inequities experienced by socially disadvantaged populations is an
80 increasing and urgent societal issue [1, 2]. The psychosocial factors contributing to these
81 disparities often begin early in life and include the prenatal environment which has
82 profound effects on fetal and infant outcomes that can last a lifetime [3-5]. How social
83 disadvantage (SD) and psychological stress (PS) becomes biologically embedded, and
84 then leads to disparate health outcomes remains unclear.

85 The gut microbiome (GM) is one candidate driver of adverse outcomes. Many SD-
86 related morbidities are associated with systemic chronic inflammation [6], and the GM, by
87 shaping and modulating the immune system [7, 8], is associated with systemic
88 inflammation and autoimmune disease, including many disorders associated with
89 populations in which SD is widespread, and include diabetes [9], obesity [10],
90 cardiovascular disease, and neurologic disorders [11].

91 The GM is itself shaped primarily by environment, with influences including
92 environmental exposures of diet, antibiotics, exercise, stress and sleep deprivation [12].

93 Many of these exposures have distinct characteristics for individuals living with economic
94 and psychosocial hardships. Despite increasing awareness of an intersection between
95 the GM and psychosocial inequities [13, 14], few human studies [15-17] have examined
96 the impact on gut microbial community structure and function, particularly in the perinatal
97 period. Studies in pregnant women have focused on either maternal psychological state
98 [18-22] or socioeconomic status [23-25] but not both, have used 16S RNA analysis, which
99 limits, taxonomic and metabolic pathway identification, and have not linked mother-infants
100 samples to examine maternal transfer within this context.

101 This study aims to fill these knowledge gaps. Using a prospective cohort
102 assembled prenatally, we identify the distinct impact of exposure to SD and PS on GM
103 structure and functions for mothers and their infants. We identify discriminatory taxa
104 driving this association using whole metagenomic shotgun (WMS) sequencing, and
105 attempt to relate systemic inflammation to the GM by examining maternal prenatal serum
106 cytokines. Understanding the interaction of the gut microbiome with social determinants
107 of health holds great promise for future preventions due to its potential alterability and
108 plasticity over time. This is particularly true for the perinatal period, a critical
109 developmental window in which perturbations in GM community structure and functions
110 have long-lasting effects [26-28].

111

112 **RESULTS AND DISCUSSION**

113 A subset of 121 mother–child dyads were drawn from the larger parent study, Early Life
114 Adversity Biological Embedding and Risk for Developmental Precursors of Mental
115 Disorders (eLABE), which enrolled mothers prenatally and followed their infants after

116 brith. These 121 mothers were drawn from across the psychosocial spectrum and
117 representative of the parent cohort with average ages of 29.8 (\pm 5.1 years) vs. 29.2 (\pm 5.3
118 years), similar dietary Healthy Eating index profiles 59 (\pm 10.6%) vs 58 (\pm 9.9%), and
119 gestational age at delivery 39.0 (\pm 1.1wks) vs. 38.3 (\pm 2 weeks). Mothers and their
120 children were classified based on composite scores from two latent constructs, SD and
121 PS [29]. The SD construct included 7 individual domains across income, neighborhood
122 deprivation, insurance, and education. The PS construct included 9 individual domains
123 across depression, stress, short term and lifetime, and racial discrimination (see Methods
124 for details). To define an effect of SD from that of PS on the maternal and children
125 microbiome, we examined the interrelationships among pre- and post-natal adversity and
126 circulating cytokines as biomarkers of inflammation, with the GM. The mothers' GM was
127 profiled using third trimester stool samples before parturition (average -18.0 ± 16.9). Their
128 children's stools at were sampled 130.4 (\pm 13.1) days after birth. Circulating cytokines
129 were analyzed in maternal blood samples obtained during the 3rd trimester of pregnancy.
130 Participant characteristics are provided in **Table 1** and **Supplementary Table S1**.

131
132 **Maternal SD and PS relation to maternal and child pre- and post-natal GM structure**
133 **and function, based on high level taxonomic profiling**

134 We performed targeted metagenomic sequencing (see Methods) for 121 mother-child
135 dyads (**Figure 1**). Among the 121 mother-child dyads (**Figure 1A**), the SD scores were
136 positively correlated with PS scores ($r = 0.394$, $P < 10^{-5}$; **Figure 1B**), corroborating the
137 literature [30] and demonstrating the importance of differentiating effects from these two
138 overlapping variables. Several variables, including race, breast milk feeding frequency,

139 healthy eating index and income-to-needs ratio, were significantly associated with high-
140 vs-low SD and PS scores, also expected because these variables were used as inputs to
141 calculate these scores [29] (**Table 1; Supplementary Table S1**).

142 Across all samples, 3,072 amplicon sequence variants (ASVs) representing
143 unique 16S nucleotide sequences were detected. Relative abundance values per ASV
144 per sample are provided for all 242 samples in **Supplementary Table S2**, and nucleotide
145 sequences for each identified ASV are provided in **Supplementary Table S3**. In the
146 mothers, SD and PS scores had an overall negative correlation with α -(within sample)
147 diversity based on the bacterial taxonomic composition, although this correlation was not
148 significant (**Figure 2A**), consistent with previous reports of decreased α -diversity
149 associated with lower Socioeconomic Status (SES) [15-17]. In contrast, among the
150 children, α -diversity was positively correlated with SD ($r = 0.581$, $P < 10^{-5}$) and PS scores
151 ($r = 0.350$, $P = 8.3 \times 10^{-5}$) (**Figure 2B**). This observation may be partly explained by the
152 lower frequency of breast feeding in the high-SD mothers (**Figure 2B**), as it is reported
153 that breast-fed infants had lower GM α -diversity compared to formula-fed infants at three
154 months of age, but the GM diversity increased by six months [31].

155 An examination of the similarity between mother and child GM (β -diversity)
156 measured by the Bray-Curtis statistics, showed that mother-child dyads with low-SD
157 scores had significantly less similarity ($P < 10^{-5}$, **Figure 2C**). This may be partially due
158 differences in α -diversity, where formula-fed/high-SD infants have GM that are more
159 similar to their mother's GM because of greater overall α -diversity. Bray-Curtis
160 dissimilarity-based clustering identified significant associations between SD scores and
161 PS scores in the microbiome profiles in the children, but not in the mothers (**Figures 2D-**

162 **2G**). We identified four major GM clusters in the mothers, but none significantly differ in
163 SD or PS (**Figures 2D** and **2E**). We also identified four major sample clusters in children,
164 with cluster 4 having significantly greater SD scores than the other three clusters (ANOVA
165 $P < 10^{-5}$), and also higher PS scores than clusters 1 and 3 (ANOVA $P = 3.1 \times 10^{-4}$) (**Figures**
166 **2F** and **2G**). These results suggest that high-SD and high-PS scores are significantly
167 associated with a distinct overall GM profile in the children, but not in the mothers.

168 We next compared Bray-Curtis similarity between each sample dyad, within and
169 between high and low SD and PS groups (**Figure 3**). High-SD mothers had significantly
170 more variable microbiome profiles than those of low-SD mothers, who presumably had
171 more consistent healthy microbiome profiles. This effect was even stronger for the PS
172 comparison, with low-PS mothers having the most similar GM to each other than in any
173 of the other comparisons, and the high-PS mothers having as similar between-sample
174 diversity as the low-SD mothers (**Figure 3A**). High-SD children had the most similar
175 microbiome profiles (**Figure 3B**), which may relate to their increased α -diversity (**Figure**
176 **2B**). Low-SD children also have some overall similarity in their GM profiles, but the low-
177 SD and high-SD children GMs have little similarity (consistent with clustering results in
178 **Figure 2F**). The same is true for PS in the children, except the within-group similarity for
179 low-PS and high-PS were not significantly different. Overall, these results suggest that
180 high-SD and high-PS mothers have divergent, variable microbiomes compared to low-SD
181 and low-PS mothers, who share some commonality in overall GM profiles. Taken
182 together, these results suggest that high-SD and high-PS mother already have
183 compromised GM resulting in low observed inter-individual similarity compared to the low-
184 SD and low-PS group, which has a more similar and healthier mature GM.

185
186 **Species-level gut microbiome profiles and metabolic pathway reconstructions of**
187 **89 mother–child dyads**

188 We performed WMS sequencing on a subset of stools from 89 of the 121 mother–child
189 dyads, selected based on the distribution of SD and PS scores (**Figure 1C**) (greater and
190 less than the average value + 0.5 and – 0.5 standard deviations). The profiles of the 178
191 GMs (89 mothers and their 89 children), were generated from an average of 6Gb reads
192 per sample, characterized using the Unified Human Gastrointestinal Genome (UHGG)
193 [32]. Relative abundance values per species per sample were calculated using
194 normalized depths [33] for downstream analysis. A total of 2,219 bacterial genomes were
195 detected across all samples (**Figure 4A**). Genome taxonomic annotations and relative
196 genome abundance values per sample are provided for all 178 samples (**Supplementary**
197 **Table S2**). Twelve genomes were detected frequently across all mothers and all children
198 samples ($\geq 40\%$ of both), including five *Bifidobacterium* genus members (*B. infantis*, *B.*
199 *breve*, *B. bifidum*, *B. catenulatum* and *B. adolescentis*), with *Bifidobacterium infantis* being
200 the most frequently detected genome across all samples (69.7% of mothers and 89.9%
201 of children). These 12 also included two *Bacteroides* species (*B. dorei* and *B.*
202 *xylanisolvans*), two *Faecalicatena* species (*F. gnavus* and *F. unclassified*), *Flavonifractor*
203 *plautii* and *Eggerthella lenta* (**Figure 4B**). Four of these species were also identified as
204 “core mother-infant shared species” in a previous WGS study [34], however the limited
205 overlap may be in part a result of using different genome reference databases (identifying
206 clade-specific marker genes from MetaPhlan2 [34, 35] vs mapping to the Unified Human
207 Gastrointestinal Genome (UHGG) [32]) in these 2 studies.

208 We next reconstructed the metabolic pathways to compare the functional potential
209 of the GM communities (based on the relative abundance of metabolic pathways [36] in
210 read counts per million, CPM) using HUMAnN3 [37-39]. A total of 468 pathways were
211 detected across all samples, 438 of which were detected in at least 3 mother or 3 children
212 GMs (**Figure 4C**). Relevant pathway annotations and relative pathway abundance values
213 per sample are provided for all 178 samples (**Supplementary Table S2**). In contrast to
214 the genomes with relatively sparse identification across samples, almost half (46.3%) of
215 all detected pathways were identified in $\geq 90\%$ of samples in both the mothers and the
216 children (top right of the plot, **Figure 4D**), including 130 pathways (27.8%) detected in all
217 178 samples. Despite the taxonomic differences between the GM of mothers and children
218 (31.71% shared genomes; **Figure 4A**), the core set of microbial functions is conserved
219 across the groups with 87.2% of the pathways being encoded by both mothers and
220 children's GMs (**Figure 4C**). This greater similarity between mothers and children in their
221 microbial metabolic pathways compared to their microbial taxonomic profiles has been
222 observed previously, and may be attributed to "core" microbial community functions
223 essential for all species, despite the distinct populations of species adapted to different
224 diets at different stages of life [34].

225

226 **Bacterial species discriminating between mothers SD and PS**

227 To dissociate the impact of the highly inter-related SD from PS on the maternal GM, and
228 to identify discriminatory bacterial taxa that are strong predictors of mother's SD and PS
229 scores, we analyzed taxonomic and pathway GM profiles using two statistical
230 approaches. First, we used supervised Random Forest (RF; [40]) machine-learning was

231 used with a two-round approach [41] to (i) quantify the ability to predict SD and PS
232 classification based on the mothers' and the childrens' microbiome profiles (**Figure 5**),
233 and (ii) identify the specific genomes and pathways that most strongly differentiate
234 between the high and low SD and PS scores (**Figures 6 and 7**; see Methods). Second,
235 we used linear discriminant analysis effect size (LEfSe; [42]) to test differential genome
236 and pathway abundance testing, to assign P values and “effect size” values for
237 significance, as additional validation of RF results. Differential abundance statistics for all
238 genomes and all comparisons are provided in **Supplementary Table S4**.

239 We identified a set of SD and PS-discriminatory bacteria (**Figure 6**) whose relative
240 abundances can classify mothers into low- or high-SD 80.5% of the time ($P = 1.4 \times 10^{-6}$
241 compared to random assignment; FDR-corrected binomial distribution test; AUC = 0.862,
242 $P = 7.1 \times 10^{-8}$, Wilcoxon rank sum test), and as low- or high-PS 79.4% of the time (P
243 $= 1.5 \times 10^{-6}$; AUC = 0.778, $P = 8.2 \times 10^{-7}$; **Figure 5**). The best predictors of SD (**Figure 6A**)
244 and PS (**Figure 6B**) scores in the mothers were identified according to mean decrease
245 of accuracy (MDA) scores (see Methods) for each genome across the low-SD group and
246 the high-SD groups. The microbiome signature of low-SD and low-PS samples consisted
247 of bacterial species present in high abundance in most of the samples, but which were
248 detected with zero or very low abundance in the high-SD or high-PS samples (**Figure 6**).

249 Low-SD mothers are identified by increased abundance of many Firmicutes A
250 genomes (**Figure 6A**). *Lawsonibacter asaccharolyticus*, a recently-identified butyrate-
251 producing species [43, 44], was the strongest predictor of low-SD scores in the mothers
252 (MDA = 10.2%, LEfSe effect size = 2.7, $P = 3.7 \times 10^{-6}$). GM-derived butyrate has a wide
253 range of beneficial effects on health including regulating fluid transport, reducing

254 inflammation, reinforcing the epithelial defense barrier, and modulating intestinal motility
255 via mechanisms that include potent regulation of gene expression [45], but *L.*
256 *asaccharolyticus* has not been previously and independently associated with these
257 beneficial effects. *Streptococcus thermophilus* was also among the top 5 predictors (MDA
258 = 5.0%, LEfSe effect size = 3.2, $P = 1.7 \times 10^{-4}$) and is used to produce yogurts and
259 cheeses, has properties beneficial to health including the prevention of chronic gastritis
260 and diarrhea, and immunomodulatory properties with possible benefits in inflammation
261 [46]. *S. thermophilus* was also among the predictors of low-PS, and this species was
262 detected with zero or low abundance in high-PS and high-SD individuals.

263 The predictors of high-SD and high-PS were phylogenetically quite distinct,
264 enriched for Actinobacteria and Firmicutes C, vs. mainly Firmicutes A, respectively.
265 Genomes from four *Bifidobacterium* species (*B. catenulatum*, *B. bifidum*, *B. breve* and *B.*
266 *infantis*) are among the six most strongly associated with high-SD, and *B. catenulatum* is
267 associated with high-PS as well. It is recognized that *Bifidobacteria* in the human gut vary
268 with age, and while quantitatively some are particularly important in infant GM its presence
269 with aging is stable but abundance changes over time. In general high abundance of
270 *Bifidobacteria* is related to gut homeostasis and health maintenance and protection, in
271 part by producing a number of potentially health promoting metabolites including short
272 chain fatty acids, conjugated linoleic acid and bacteriocins, and *Bifidobacteria* is
273 postulated to improve health [47]. However, qualitative and quantitative (increasing
274 abundance) in *Bifidobacteria* are associated with inflammatory disorders such as
275 diverticulitis, inflammatory bowel disease, and colorectal cancer [48]. Additionally, a
276 recent review of GM variations associated with major depressive disorder (MDD)

277 identified *Bifidobacterium* as one of three genera most consistently associated with MDD
278 across studies [49]. While the specific functional role of these high-SD associated
279 *Bifidobacteria* species is unclear, there is a striking increase in overall Bifidobacterial
280 abundance in the high-SD mothers (**Supplementary Figure S1**).

281 *Bacteroides A mediterraneensis* was most strongly associated with low-PS in
282 mothers (MDA = 10.9%, effect size = 2.5, $P = 1.5 \times 10^{-4}$; **Figure 6B**). In mice, stress
283 exposure reduces abundance of *Bacteroides* in the GM [50], and in humans, *Bacteroides*
284 is one of five genera associated with healthy status vs. MDD patients [51], the but this is
285 the first report of *Bacteroides A mediterraneensis* specifically being associated with PS in
286 a human cohort. The same human MDD study [51] also identified *Faecalibacterium* and
287 *Prevotella* as being negatively associated with MDD, and in this study *Faecalibacterium*
288 *sp.* and *Prevotella sp001275135* were the 5th and 7th strongest predictors to low-PS
289 (respectively).

290 Three species of *Blautia sp.* were among the top four most strong predictors of
291 high-PS in the mothers, and none of these four species were associated with SD,
292 suggesting a specific link with psychological stressors. In human studies, *Blautia* was one
293 of ten genera associated with MDD [51], and *Blautia* and *Eggerthella* (represented in the
294 high-PS mothers by *E. lenta*) were significantly correlated with PSS scores [52]. The latter
295 study also identified *Blautia* and *Bifidobacteria* (represented in the high-PS mothers by *B.*
296 *catenulatum*) as being significantly associated with MDD [52]. However, we wish to note
297 that the overall abundance of *Blautia* in the microbiome remained fairly consistent across
298 the mothers (**Supplementary Figure S2**), and only the species identified in **Figure 6B**
299 predict PS.

300

301 **Bacterial species in the infant GM discriminating prenatal maternal SD and PS**

302 A set of SD and PS-discriminatory bacterial genomes correctly classify children into low-
303 or high-SD in 84.6% of comparisons ($P = 6.7 \times 10^{-9}$ compared to random assignment; FDR-
304 corrected binomial distribution test; AUC = 0.920, $P = 7.0 \times 10^{-10}$, Wilcoxon rank sum test),
305 and as low- or high-PS in 82.1% of comparisons ($P = 7.7 \times 10^{-8}$; AUC = 0.889, $P = 9.8 \times 10^{-8}$)
306 **Figure 5**). The top predictors of SD score (**Figure 7A**) and PS score (**Figure 7B**) in the
307 children were identified according to MDA scores.

308 Among the predictors that are most important for classification to high-SD in
309 children and with the largest effect size are *Enterobacter nimipressuralis*, nearly absent
310 in low-SD children (detected in only one sample), and *Klebsiella pneumoniae*, both
311 proinflammatory lipopolysaccharide expressing Proteobacteria [53]. The strongest
312 predictor of children with low-SD was *B. infantis*, a species frequently used as a probiotic
313 to diminish inflammation and associated with breastfeeding [54]. *B. infantis* represented
314 an average of 28.3% of the GM of the low-SD infants, but only 5.2% of the GM in the
315 high-SD infants (MDA = 10.14%, LEfSe effect size = 5.1, $P = 0.0083$; **Supplementary**
316 **Figure S1**). The top taxa based on the comparison of the SD scores in the mothers were
317 not proinflammatory and belonged to genomes from four *Bifidobacterium* species
318 previously associated with several putatively beneficial metabolites [47].

319 There was an overlap of the predictors for low-SD and low-PS, including *Veillonella*
320 *parvula* A, and several *Collinsella* spp. *Veillonella* is a signature taxa of the 4-month
321 microbiome, and with *Collinsella* have been found in breast-fed microbiome indicating
322 reduced concentration of oxygen, increased production and utilization of lactic acid which

323 is specific for milk dominated diet [55]. The high-SD and high-PS-discriminating bacteria
324 were enriched for a broad range of evolutionarily distinct Firmicutes species (**Figure 7**).
325 The best high-PS predictors included *F. gnavus* reported as pathobiont associated with
326 inflammatory bowel disease [56] and *Sutterella* sp. *Sutterella* species are prevalent
327 commensals in the human GM with mild-proinflammatory properties [57].

328

329 **Metabolic pathways associated with SD and PS in mothers and children**

330 The relative genomic abundance data from the WMS dataset has more features and more
331 taxonomic specificity than metabolic pathway abundance data, because pathways are
332 much more conserved across samples (**Figure 4**). Genomic data therefore enables better
333 estimation of overall GM associations with SD and PS scores (**Figure 5**). Nevertheless,
334 the same statistical approaches (see Methods; RF and LEfSe) were used to identify sets
335 of SD- and PS-discriminatory metabolic pathways in the mothers and in the children
336 (defined here using MetaCyc, a curated database of experimentally elucidated metabolic
337 pathways from all domains of life [36]). Differential abundance statistics for all pathways
338 and all comparisons are provided in **Supplementary Table S5**.

339 Based on metabolic pathway profiles, machine learning correctly classifies
340 mothers as high- and low-SD in 71.8% of comparisons ($P = 8.5 \times 10^{-4}$) and as high- and
341 low-PS in 69.1% of comparisons ($P = 0.0023$). The top predictive pathways for both
342 comparisons are shown in **Table 2**. The pathways with greatest association with high-SD
343 in mothers include three related to carbohydrate degradation (sucrose degradation IV,
344 glycogen degradation I, starch degradation III), which might relate to the accompanying
345 abundance of *Bifidobacterium* species, which are rich in carbohydrate metabolism

346 pathways [58]. The “myo-, chiro- and scyllo-inositol degradation” pathway (PWY-7237)
347 was most strongly associated with high-PS in mothers (MDA = 5.95, $P = 2.1 \times 10^{-3}$). Myo-
348 inositol and chiro-inositol degradation by the gut microbiome contributes to inositol
349 deficiency [59], which includes metabolic disorders involved with insulin function [59] and
350 MDD when myo-inositol is deficient in the prefrontal cortex [60].

351 Children are classified correctly as high- and low-SD in 85.9% of comparisons (P
352 = 1.3×10^{-9}) and as high- and low-PS in 72.1% of comparisons ($P = 4.1 \times 10^{-4}$) based on
353 pathway abundance profiles. The top predictive pathways for both of these comparisons
354 are shown in **Table 3**. Synthesis of L-glutamate and L-glutamine (PWY-5505) was the
355 pathway most strongly associated with high-SD in the children (MDA = 7.9%, $P = 7.9 \times 10^{-7}$),
356 and has been previously associated with obesity and visceral fat accumulation [61].
357 Here, L-glutamine biosynthesis was also associated with high-SD in both mothers and
358 children. In supplementation studies of the gut microbiome, glutamine reduces the ratio
359 of Firmicutes to Bacteroidetes and bacterial overgrowth or bacterial translocation, and
360 increases the density of secretory immunoglobulin A (IgA) and IgA+ cells in the intestinal
361 lumen [62].

362

363 **Bacterial species discrimination between SD and PS groups based on maternal** 364 **circulating cytokines**

365 The relationship between inflammation and the GM is examined through maternal
366 systemic cytokines IL-6, IL-8, IL-10 and TNF alpha, measured across trimesters. In
367 mothers, prediction accuracy of the GM was greatest for third trimester cytokine samples,
368 consistent with timing of maternal stool samples. Prediction accuracy was consistently

369 greater for IL-6 than for the other inflammatory markers (**Table 4**). Discriminatory bacterial
370 genomes demonstrate the most consistent and greatest predictive accuracy for IL-6,
371 which in preclinical models is centrally important in altering fetal brain development in
372 maternal immune activation models, where placental inflammatory signals are relayed to
373 the fetal brain [63-65]. We identified a set of discriminatory taxa from maternal third
374 trimester stools, whose relative abundance successfully classify mothers into low- or high-
375 IL-6 75.6% of comparisons ($P = 2.2 \times 10^{-4}$; **Supplementary Figure S3**) vs. random
376 assignment (FDR-corrected binomial distribution test), and in 72.1% of comparisons of
377 metabolic pathways ($P = 2.2 \times 10^{-4}$). In this case, high prenatal IL-6 concentrations are
378 associated with the lower abundance of anti-inflammatory *Bacteroides* species, as
379 evidenced by the RF and LEfSe significance (effect size 2.3, $P = 0.017$ for *Bacteroides A*
380 and effect size 2.9, $P = 0.02$ for *Bacteroides faecis*), as reported in other inflammatory
381 states [47, 66]. These data illustrate the importance of community balance, including
382 presence and absence, on target outcomes, and the importance in the ability to identify
383 these at species/strain levels. Interestingly, we also identified discriminatory taxa in the
384 infant 4-month GM profile (**Figure 8**). Of all inflammatory marker comparisons, microbial
385 genomes in children had the best overall accuracy for maternal third trimester IL-6
386 concentrations (high/low) based on relative abundance (77.8% accuracy, $P = 6.0 \times 10^{-5}$)
387 and metabolic pathways (75.6%, $P = 6.9 \times 10^{-4}$). However, maternal IL-6 concentration
388 was not significantly correlated with SD or PS in this subsample (**Supplementary Figure**
389 **S4**), although higher SD is associated with higher maternal IL-6 in the full sample set.
390 Thus, the relationship of the maternal GM to IL-6 is driven by taxa distinct from those
391 identified in composite SD or PS values, but still have proinflammatory characteristics.

392

393 **CONCLUSIONS**

394 Our prospectively assembled cohort of mother-infant dyads, enabled us to quantify for
395 the first time the impact of exposure to both, SD and PS on GM structure and function for
396 mothers and their infants. Mothers and infants classified as “high’ (case) or “low” (control)
397 SD/PS, show distinct discriminatory taxonomic, metabolic and inflammatory features that
398 accurately ‘predict’ maternal prenatal SD and PS status over 80% of the time, with SD
399 having greater predictive accuracy than PS. Mothers with high-SD/high-PS have highly
400 variable microbiomes compared to low-SD/low PS mothers, reflecting greater
401 permutations from environmental influences. The distinct nature of the taxonomic and
402 functional GM predictors for SD compared to PS, indicate different underlying
403 mechanisms driving the relationship.

404 The human GM modulates inflammatory cytokine production [8, 67] and has been
405 linked to chronic inflammatory disorders [6]. We identified a significant relationship
406 between the maternal prenatal and infant GM, and prenatal circulating cytokine
407 concentrations in mothers. Prediction accuracy is highest and most consistent for IL-6
408 suggesting a contributing role to subtle chronic inflammation, although the discriminating
409 taxa are distinct from SD. Elevated IL-6 concentrations have been linked to specific GM
410 profiles in disease states among adults [68, 69] and recently to neuropathology when
411 elevated during pregnancy in animal models [64, 65].

412 Our findings should be viewed within the strengths and limitations of the study.
413 The finding are associations, and do not necessarily imply causality. Identification of
414 strain level taxa and metabolic pathways through WMG, however, form the basis for

415 testing mechanistic causation in preclinical models. Use of mother- infant dyads allowed
416 interrogation of SD and PS between mother and infant GM, and examination of
417 genomes and metabolic pathways. The population we studied is from a circumscribed
418 region but contains a broad range of socio-economic backgrounds. We did not examine
419 the role of race, because of the collinearity of race and SD, with no additional
420 contribution of race in the model beyond that found with SD alone.

421 While longitudinal studies are needed to determine the stability of these GM
422 signatures from early life to early childhood in children, the results identify unique features
423 of the maternal and infant GMs and host response. Such findings should be pursued to
424 better understand the effect of socioeconomic status and mental health determinants on
425 GM health and stability. More critically, information on causal pathways triggered or
426 sustained by the GM that affect child health and development could lead to new
427 biomarkers and interventions. The potential malleability of the GM leaves room for
428 optimism that unfavorable neurodevelopment outcomes might not be inevitable in
429 children with living with high SD and PS values.

430

431 **METHODS**

432 **Study Design and Cohort**

433 The study population Consists of 121 mother-child dyads drawn from a larger parent
434 study of 399 dyads, Early Life Adversity Biological Embedding and Risk for
435 Developmental Precursors of Mental Disorders (eLABE; details provided in [29]). The
436 eLABE study used a prospective observational design to examine the impact of pre- and
437 post-natal psychological and social factors on infant neurodevelopment. Pregnant

438 women (N=395) and their offspring were recruited from the March of Dimes Prematurity
439 Research Center at Washington University in St. Louis between 2017-2020, with delivery
440 of singleton births at the Barnes Jewish Hospital in St. Louis [70]. This sub-cohort was
441 chosen from the extremes of maternal social disadvantage and psychosocial stress,
442 among women with relatively healthy offspring, who donated third trimester stools.
443 Exclusions included multiple gestation, congenital malformations and infections,
444 premature birth (< 37 weeks gestational age), maternal alcohol or drug use during
445 pregnancy (excluding tobacco, marijuana, and maternal enteral steroid use). Race and
446 ethnicity were based on maternal self reporting extracted from the medical record.
447 Options included American Indian/Alaskan Native, Asian, Black or African American,
448 Native Hawaiian/Pacific Islander, White, unknown, or other (free text) for race, and the
449 following options for ethnicity: Hispanic/Latina, non-Hispanic/Latina, or unknown/not
450 applicable for ethnicity. All procedures were approved by the Human Research Protection
451 Office, informed consent was obtained from the mother for each dyad. The study was
452 performed in accordance with Strengthening the Reporting of Observational Studies in
453 Epidemiology (STROBE) guidelines [71].

454

455 **Maternal measures**

456 At each trimester of pregnancy, measures of maternal depression, experiences of stress,
457 as well as demographic information including insurance, education, address, and
458 household composition were obtained from participants or extracted from the medical
459 record by trained staff. Components of the two latent constructs, maternal social

460 disadvantage and maternal psychosocial stress are previously described [29]. Briefly, the
461 components of each latent variable included:

462

463 Maternal Social Disadvantage: Insurance status obtained was verified at the third
464 trimester from the medical record and maternal self reporting, Income to Needs ratio in
465 each trimester based on family income and household size (1.0 being the poverty line for
466 the U.S.) was self reported, highest maternal educational level was self reported, the
467 national Area Deprivation Index is a national multidimensional geotracking method based
468 on census block data, providing percentile rankings of neighborhood disadvantage status
469 [72], and maternal nutrition over the past year was categorized using the validated
470 Healthy Eating Index (using National Cancer Institute. The Healthy Eating Index –
471 Population Ratio Method. Updated December 14, 2021; [73]) obtained using the
472 Diet History Questionnaire (DHQII).

473 Maternal Psychosocial Stress: In each trimester mothers completed the Edinburgh
474 Postnatal Depression Scale (EPDS) [74], Perceived Stress scale (PSS) [75] at each
475 trimester, averaged over trimesters a one-time lifetime STRAIN survey [76], a
476 comprehensive measure of lifetime stressful and traumatic life events. Experiences of
477 discrimination based on race were assessed using the Everyday Discrimination Scale
478 [77].

479 Maternal medical risks: were defined by the Maternal Medical Risk score in pregnancy, a
480 validated measure of maternal co-morbidities weighted by severity in pregnancy, and
481 maternal pre-pregnancy Body Mass Index was extracted from the medical record.

482

483 **Infant measures**

484 Gestational age was determined by the best obstetric estimate using last menstrual
485 period or earliest ultrasound dating. Birthweight and route of delivery were extracted from
486 the electronic medical record delivery note. Breastfeeding data was collected by parental
487 reporting at the time of home stool sample collection and based on the Center for Disease
488 Control Infant Feeding Practices II study food frequency checklist data [78, 79].

489

490 **Biological specimen collection and processing**

491 Maternal blood samples for serum were collected from venous draws during routine clinic
492 visits across each trimester, processed within 12 hours of collection, and stored at -80°C
493 in 1 mL aliquots (details in [70]). Stools from mothers and infants were collected from
494 home and processed as previously described [79]. Briefly maternal samples were
495 collected during the third trimester, and infant stools were retrieved directly from the
496 diaper and scooped into barcoded tubes. Stool samples were placed in insulated
497 packaging (VWR) with U-tex gel packs (Fischer Scientific) and placed in home freezers.
498 A community-based courier system available 24 hours per day was used to retrieve
499 samples within 90 minutes. Weekend or overnight samples were taken to the courier
500 office freezers (-20°C) and then delivered to the laboratory freezer (-80°C) during working
501 hours; weekday stools were couriered directly to the laboratory. Previous testing showed
502 no quality difference between temperatures used in delivery methods [80]. DNA was
503 extracted from stool using the Qiagen (Hilden, Germany) QIAamp Power Fecal Pro DNA
504 Mini Kit (50) and the automated QIAcube platform (Qiagen) as previously described [79,
505 81].

506

507 **Targeted GM profiling using V4-16S rRNA sequencing, data processing and**
508 **analyses**

509 DNA extracted from stool was sequenced on an Illumina MiSeq, producing 2x250bp
510 paired-end reads spanning the V4 hypervariable region, for 242 samples (121 samples
511 from mothers and 121 from their matched children). Data were imported into QIIME2
512 [82], using standard methods and the developer's docker container (qiime2/core:2018.8).
513 V4 region amplicons were assembled and denoised using the Qiime2 method 'DADA2
514 denoise-paired'. Processed V4 amplicons were grouped into amplicon sequence variants
515 (ASVs) with 100% sequence similarity. ASVs were classified using a pre-trained classifier
516 based on SILVA (release 132) [83], a comprehensive database that provides accurate
517 annotations [84]. ASV counts per sample were exported as biom files from a qiime2
518 artifact and converted into a human readable tsv file using "biom convert". Read counts
519 per sample were rarefied to 11,929 reads per sample (the lowest count among the 242
520 samples) using the "rrarefy" command in the R package "vegan" (version 2.5-7,
521 <https://CRAN.R-project.org/package=vegan>), and normalized read counts were
522 calculated per sample by dividing the number of reads associated with each ASV by the
523 total number of reads assigned across ASVs. Taxonomic identifications used are directly
524 provided by SILVA [83]. Raw 16S rRNA can be downloaded from public database
525 (submission in progress).

526

527 **Whole Metagenome Shotgun (WMS) sequencing and GM profiling**

528 Whole Metagenome Shotgun (WMS) datasets for 178 samples (89 samples from mothers
529 and 89 from their respective children) were generated on the Illumina NovaSeq S4. For
530 each sample ~ 6Gbp was generated. The reads for all 178 samples were cleaned of
531 barcodes, adapters and low-quality ends using Trimmomatic [85] (version 0.36). The
532 BMTagger program (installed using conda, July 30th, 2020) was used to identify human
533 contaminant reads using the human reference genome (GRCh38.98 [86]). Reads
534 identified as human were removed to produce final paired-end fastq per each of the 178
535 samples. Raw WMS read data can be downloaded from public database (submission in
536 progress).

537 The 178 WMS samples were mapped against the Unified Human Gastrointestinal
538 Genome (UHGG) collection, comprising 204,938 nonredundant genomes from 4,644 gut
539 prokaryotes, each theoretically representing an individual bacterial or archaeal species
540 (95% average nucleotide identity [32]) using bowtie2 [39] (v2.3.5.1). The profile module
541 of the inStrain [33] program was then run to generate sequencing breadth and depth of
542 coverage statistics for every genome, in addition to nucleotide diversity measures per
543 genome per sample. The depth of coverage values were normalized within every sample
544 by dividing each genome's depth by the sum of the depths across all genomes.

545 The 178 WMS samples were also used as input for HUMAnN [37] (version 3),
546 which was ran from the biobakery/humann docker container (latest version as of October
547 2020) using the Chocophlan nucleotide database and Uniref90 [87] protein database.
548 HUMAnN3 runs the MetaPhlan [38] program as an intermediate step to assign organism-
549 specific functional profiling, and we used the developer-provided Metaphlan3 [38] bowtie2
550 [39] database for this intermediate step. The HUMAnN3 pipeline was used to generate

551 MetaCyc [36] pathway abundance per sample. The “humann_renorm_table” script
552 (included in the HUMAnN3 distribution) was used to convert Reads Per Kilobase (RPK)
553 values in the MetaCyc abundance table to a normalized value, Copies Per Million (CPM),
554 which can be compared across samples.

555

556 **Statistical analysis**

557 Significant differences between Low and High SD and PS sample sets based on
558 metadata classifications (**Table 1, Supplementary Table S1**) were calculated using two-
559 tailed T-tests with unequal variance for continuous variables and using Fischer exact tests
560 for categorical data. Correction for multiple testing was not performed across tests,
561 because significant differences indicate potential bias in the data. Significant differences
562 in components of SD and PS were expected since samples were chosen from the
563 extremes of phenotype for SD and PS to improve detection of GM differences between
564 groups [29].

565 For the 16S/ASV sample analysis, Shannon index diversity values were calculated
566 for each sample using the normalized read counts across all taxa using the “diversity”
567 function in the “vegan” library in R, and Bray-Curtis distance diversity values were
568 calculated using the “vegdist” function [88]. Correlation R^2 values and Pearson r values
569 were calculated using MS Excel, and the significance of the correlation was tested using
570 the two-tailed t statistic with degrees of freedom $N - 1$. ASV-based sample clustering was
571 performed using the relative abundance profiles of all ASVs across all samples as input
572 for Bray-Curtis dissimilarity-based clustering (complete linkage) using the “hclust”
573 function in R, with additional metadata visualized using MS Excel. Significant differences

574 in SD and PS between clusters were identified using ANOVA with a Post Hoc Tukey HSD
575 test.

576 For the WMG sequence analysis, samples were divided into “high” and “low” SD
577 and PS based on the distribution of these values across the sample set. Samples above
578 the average value + 0.5 standard deviations were considered “high” and samples below
579 the average value – 0.5 standard deviations were considered “low” (35 “low-SD”, 43 “high-
580 SD, 36 “low-Psych” and 32 “high-Psych”; **Figure 1C**). The same approach was used to
581 separate samples into “high” and “low” sample sets based on inflammatory marker data
582 (IL-6, IL-8, IL-10 and TNF α).

583 To identify bacterial taxa that strongly predict mothers’ SD and PS scores, we
584 analyzed taxonomic and pathway GM profiles using two approaches. First, a supervised
585 machine-learning approach (Random Forest [40]) that identifies non-linear relationships
586 from high dimensional and dependent data [40] and two-round approach using only the
587 best 25 predictors (as previously described for gut microbiome associations with mental
588 health measures [41]) was used to (i) quantify the ability to predict metadata classification
589 based on the microbiome profiles, indicative of the overall association between the
590 microbiome and the composite scores, and (ii) for each comparison, identify the specific
591 genomes and pathways that most strongly differentiate between the high and low SD and
592 PS scores. The generalization error of the model was evaluated by out of bag (OOB)
593 error. The association of the metadata with the microbiome was quantified using the RF
594 classification accuracy, and the significance of the accuracy was measured using FDR-
595 corrected binomial distribution tests. RF model accuracy was also examined using
596 receiver operating characteristic (ROC) curves, quantified using the area under the curve

597 (AUC). Significance values for the ROC curves were assigned by Mann-Whitney U
598 statistics [89], using the “roc.area” function in the R library “ROCR”.

599 Second, linear discriminant analysis effect size (LEfSe [42]), the most frequently
600 used statistical tool to determine significant differences in microbiome member
601 abundance [90], was used for differential genome abundance testing (default settings at
602 an adjusted $P \leq 0.05$ for significance) for the non-parametric factorial Kruskal-Wallis (KW)
603 sum-rank test, and requiring a linear discriminant analysis (LDA) “effect size” of at least
604 2 in order to identify differentially abundant taxa). The same approach was used for the
605 pathway analysis, but the “effect size” test cutoff applied was reduced to a value of 1
606 instead of 2, since the effect size is designed for the more sparse nature of metagenomic
607 abundance data [42]. However, the same MDA and KW cutoffs were applied for pathway
608 analysis.

609

610 **Figure legends**

611 **Figure 1:** Overview of cohorts. (A) Portrayal of the 16S rRNA and WMS sample sets. (B)
612 Social Disadvantage (SD) scores are positively correlated with Psychological Stressor
613 (PS) scores (across the 121 sample pairs). (C) The 89 WMS samples are divided into
614 “low-SD”, “high-SD”, “low-PS” and “high-PS” groups based on the distribution of values
615 (samples within 1 standard deviation of the average value for each variable are excluded).

616

617 **Figure 2:** GM sample diversity and composition comparisons with Social Disadvantage
618 (SD) and Psychological Stressors (PS) scores. (A) SD scores and PD scores do not
619 significantly correlate with GM α -diversity (Shannon diversity index) in the 121 stool

620 samples from mothers. **(B)** α -diversity in the children is positively correlated with SD ($P <$
621 10^{-5}) and PS ($P = 8.3 \times 10^{-5}$) scores. Relative proportions of human milk feeding are also
622 shown, to provide additional context for potential sources of differential diversity. **(C)** β -
623 diversity, measured by Bray-Curtis dissimilarity between the GM of each mother-child
624 dyad, is positively correlated with SD ($P < 10^{-5}$) and PS ($P = 1.9 \times 10^{-3}$) scores. **(D)**
625 Hierarchical clustering (based on Bray-Curtis dissimilarity across all ASVs, complete
626 linkage) identifies four major GM profile-based clusters in the mother. **(E)** No significant
627 differences in SD or PS scores were identified between the four clusters based on
628 maternal GM profiles (one-way ANOVA). **(F)** Hierarchical clustering identifies four major
629 GM clusters in the children. **(G)** Among the GM clusters in children, cluster 4 has greater
630 SD (one-way ANOVA $P < 3.4 \times 10^{-5}$) and PS (3.1×10^{-4}) scores. Tukey post-hoc tests were
631 used to identify significant differences between each cluster, $*P \leq 0.05$, $**** P \leq 10^{-4}$, $*****$,
632 $P \leq 10^{-5}$.

633
634 **Figure 3:** Comparisons of β -diversity between sample sets based on high-vs-low SD and
635 PS, quantified by Bray-Curtis similarity between sample pairs, and FDR-corrected two-
636 tailed T-tests with unequal variance used to test significance **(A)** Comparisons of within-
637 and between-group β -diversity of the GM for mothers with high-SD, low-SD, high-PS and
638 low-PS. **(B)** Comparisons of within- and between-group GM β -diversity in children with
639 high-SD, low-SD, high-PS and low-PS.

640
641 **Figure 4:** Genome and pathway detection in the 89 mother and 89 child WMS samples.
642 **(A)** The total number of bacterial genomes and genomes with species-level taxonomic

643 annotation detected in at least 3 maternal samples and/or at least 3 child samples. **(B)**
644 For each of the 2,219 bacterial genomes detected in any sample, the proportion of mother
645 and child samples that were detected in the dataset. **(C)** The total number of metabolic
646 pathways detected in the GM from at least 3 mother and at least 3 child stools. **(D)** For
647 each the 468 metabolic pathways detected in any sample, the proportion of mother and
648 child samples with detection in the dataset.

649

650 **Figure 5:** The Random Forest (RF) classification accuracy (low-SD vs high-SD and low-
651 PS vs high-PS, out-of-bag error) based on relative UHGG genome abundance in the
652 mothers and children. **(A)** Overall classification accuracy, with *P* values indicating
653 significance based on FDR-corrected binomial distribution tests (compared to random
654 sample assignment). **(B)** For each of the four classification tests, receiver operating
655 characteristic (ROC) curves are shown based on RF models, with the area under the
656 curve (AUC) scores and associated Wilcoxon rank sum test results for each ROC curve
657 indicated.

658

659 **Figure 6:** WMS genome differential abundance in the mothers, based on comparisons of
660 high-vs-low SD scores and high-vs-low Psych scores. **(A)** Based on WMS genome
661 profiles, RF can successfully classify mothers as having low and high SD 80.5% of the
662 time ($P = 1.4 \times 10^{-6}$ compared to random assignment; FDR-corrected binomial distribution
663 test). Taxonomy and relative abundance per sample for the genomes with the highest
664 predictive value in the top-25 RF model are shown (ranked by mean decrease in accuracy
665 of the RF model; MDA). Also displayed are -Log of the Kruskal-Wallis test *P* values from

666 LEfSe (no value shown if the effect size was <2) and the overall abundance of the taxa
667 when present. **(B)** Based on WMS genome profiles, Random Forest (RF) can
668 successfully classify mothers into high and low Psych groups 79.4% of the time ($P =$
669 1.5×10^{-6}). *Associated with low-SD in the children, **associated with high Psych in the
670 children.

671
672 **Figure 7:** WMS genome differential abundance in the children, based on comparisons of
673 high-vs-low Social Disadvantage (SD) scores and high-vs-low Psychological Stressors
674 (PS) scores. **(A)** Based on WMS genome profiles, Random Forest (RF) can successfully
675 classify children as low- and high-SD 84.6% of the time ($P = 6.7 \times 10^{-9}$ compared to random
676 assignment; FDR-corrected binomial distribution test). Taxonomy and relative abundance
677 per sample for the genomes with the highest predictive value in the top-25 RF model are
678 shown (ranked by mean decrease in accuracy of the RF model; MDA). Also displayed
679 are -Log of the Kruskal-Wallis test P values from LEfSe (no value shown if the effect size
680 was <2) and the overall abundance of the taxa when present. **(B)** Based on WMS genome
681 profiles, RF can successfully classify children into high and low-PS groups 82.1% of the
682 time ($P = 7.7 \times 10^{-8}$). *Associated with high-SD in the mothers, **associated with low Psych
683 in the mothers, ***also associated with high-PS in the mothers.

684
685 **Figure 8:** MGS genome differential abundance in children, based on comparisons of high-
686 vs-low IL-6 abundance. Based on MGS genome profiles, Random Forest (RF) can
687 successfully classify children into high and low IL-6 abundance 77.8% of the time ($P =$
688 6.0×10^{-5}) compared to random assignment; FDR-corrected binomial distribution test).

689 Taxonomy and relative abundance per sample for the genomes with the highest
690 predictive value in the top-25 RF model are shown (ranked by mean decrease in accuracy
691 of the RF model; MDA). Also displayed are -Log of the Kruskal-Wallis test P values from
692 LEfSe (no value shown if the effect size was <2) and the overall abundance of the taxa
693 when present.

694

695

696 **Table 1.** Patients characteristics at study entry for each of the primary comparisons of
 697 interest. "Low" and "High" Disadvantage and Psych scores are separated according to
 698 the distribution of the metadata, as shown in **Figure 1**. Complete characteristics of all
 699 samples organized per individual sample is available in **Supplementary Table S2**.

Comparison type	Statistic	All 16S samples	MGS samples					
			All	Disadvantage score		Psych		
				Low	High	Low	High	
	# Sample pairs (Mother and Child)	121	89	35	43	36	32	
Maternal	Mother delivery age (years)	Min	18.8	19.3	25.7	19.3	21.5	19.3
		Max	41.3	41.3	41.3	38.7	41.3	41.0
		Average ± Std. dev.	29.8 ± 5.1	30.4 ± 5.2	33.2 ± 4.4	28.5 ± 5.2	32.0 ± 4.8	28.4 ± 5.4
		P value (T-test)			3.5x10 ⁻⁵		4.5x10 ⁻³	
	Race	African American	52.1%	53.9%	2.9%	93.0%	36.1%	75.0%
		Caucasian	44.6%	42.7%	91.4%	7.0%	61.1%	21.9%
		Other	3.3%	3.4%	5.7%	0.0%	2.8%	3.1%
		P value (Fisher test)			≤ 10 ⁻⁵		1.3x10 ⁻³	
	Income:Needs ratio	Min	0.4	0.4	3.0	0.4	0.4	0.5
		Max	12.0	12.0	12.0	3.0	12.0	11.8
		Average ± Std. dev.	3.4 ± 3.2	3.6 ± 3.5	7.5 ± 2.6	0.9 ± 0.4	5.0 ± 3.9	2.0 ± 2.2
		P value (T-test)			≤ 10 ⁻⁵		1.8x10 ⁻⁴	
	Social Disadvantage Score	Min	-2.2	-2.2	-2.2	0.4	-2.2	-2.2
		Max	1.3	1.3	-0.8	1.3	1.3	1.3
		Average ± Std. dev.	-0.24 ± 1.01	-0.23 ± 1.1	-1.48 ± 0.39	0.78 ± 0.26	-0.71 ± 1.11	0.31 ± 0.81
		P value (T-test)			≤ 10 ⁻⁵		4.9x10 ⁻⁵	
	Psychological Stress Score	Min	-1.7	-1.7	-1.7	-1.4	-1.7	0.34
		Max	2.4	2.4	1.3	2.4	-0.73	2.4
		Average ± Std. dev.	-0.21 ± 0.86	-0.21 ± 0.98	-0.70 ± 0.75	0.12 ± 0.91	-1.13 ± 0.25	0.92 ± 0.51
P value (T-test)				3.8x10 ⁻⁵		≤ 10 ⁻⁵		
Perceived Stress Scale (PSS)	Min	0	0	13.7	0	13.0	8.5	
	Max	29.7	29.7	27.5	28.0	21.0	29.7	
	Average ± Std. dev.	18.9 ± 4.5	18.6 ± 5.0	18.7 ± 2.7	18.2 ± 6.3	17.3 ± 1.9	22.4 ± 4.3	
	P value (T-test)			0.63		≤ 10 ⁻⁵		
Children	Birthweight (g)	Min	2200	2200	2760	2200	2300	2200
		Max	4665	4627	4370	4627	4370	4270
		Average ± Std. dev.	3319 ± 538	3283 ± 556	3538 ± 459	3077 ± 548	3379 ± 555	3042 ± 494
		P value (T-test)			1.3x10 ⁻⁴		0.010	
	Gestational age (weeks)	Min	37	37	37	37	37	37
		Max	41	41	41	41	41	41
		Average ± Std. dev.	39.0 ± 1.1	39.0 ± 1.1	39.5 ± 0.95	38.6 ± 1.03	39.1 ± 1.1	38.7 ± 1.1
		P value (T-test)			2.3E-04		0.23	
	Child gender	Female	43.8%	40.4%	42.9%	39.5%	41.7%	46.9%
		Male	56.2%	59.6%	57.1%	60.5%	58.3%	53.1%
		P value (Fisher test)			0.82		0.81	
		Route of delivery*	NSVD	65.3%	64.0%	60.0%	67.4%	69.4%
	VAVD		6.6%	4.5%	5.7%	4.7%	2.8%	9.4%
	Cesarean section		28.1%	31.5%	34.3%	27.9%	27.8%	31.3%
	P value (Fisher test)				0.62		0.79	
	Breast milk feeding frequency	≥50%	47.9%	46.1%	71.4%	23.3%	58.3%	31.3%
		<50%	52.1%	53.9%	28.6%	76.7%	41.7%	68.8%
		P value (Fisher test)			2.9x10 ⁻⁵		0.031	

700 *NSVD Normal spontaneous vaginal delivery, VAVD vacuum assisted vaginal delivery

701 **Table 2.** Metabolic pathways differential abundance in the mothers, based on
 702 comparisons of high-vs-low SD scores and high-vs-low PS scores. Machine learning
 703 algorithm can classify mothers as low and high SD 71.8% of the time ($P = 8.6 \times 10^{-4}$
 704 compared to random assignment; FDR-corrected binomial distribution test). Average
 705 abundance and association (high or low) are shown for the pathways predictive value in
 706 the top-25 RF model (ranked by mean decrease in accuracy of the RF model; MDA), and
 707 with LEfSe effect size ≥ 1 . The $-\log$ of the Kruskal-Wallis test P values from LEfSe is also
 708 shown.

Comparison	MetaCyc pathway ID	Average abundance (CPM)			Random Forest (top 25) MDA (%)	LEfSe results	
		Low SD	High SD	Direction		Effect size	Kruskal wallis P value
Mother SD	PWY-7198: pyrimidine deoxyribonucleotides de novo biosynthesis IV	61.9	100.9	↑	8.51	1.30	9.6E-06
	PWY-5384: sucrose degradation IV (sucrose phosphorylase)	31.2	61.8	↑	7.67	1.19	2.4E-04
	*PWY-6549: L-glutamine biosynthesis III	35.2	60.1	↑	7.38	1.13	1.6E-05
	PWY-622: starch biosynthesis	26.9	64.7	↑	3.78	1.28	2.4E-04
	PWY-241: C4 photosynthetic carbon assimilation cycle, NADP-ME type	45.8	84.0	↑	2.68	1.30	2.9E-04
	PWY-5913: partial TCA cycle (obligate autotrophs)	42.4	85.9	↑	2.67	1.35	1.2E-04
	GLYCOCAT-PWY: glycogen degradation I	38.7	72.7	↑	2.17	1.21	3.6E-03
	PWY-6731: starch degradation III	22.3	42.3	↑	1.39	1.00	1.3E-03
	UDPNAGSYN-PWY: UDP-N-acetyl-D-glucosamine biosynthesis I	172.4	208.8	↑	0.91	1.27	0.015
Mother Psych	NAGLIPASYN-PWY: lipid IVA biosynthesis (E. coli)	80.9	58.2	↓	1.84	1.10	0.020
	PWY-7237: myo-, chiro- and scyllo-inositol degradation	225.9	285.6	↑	5.95	1.49	2.1E-03
	GLYCOGENSYNTH-PWY: glycogen biosynthesis I (from ADP-D-Glucose)	297.0	382.7	↑	5.77	1.60	1.9E-04
	RHAMCAT-PWY: L-rhamnose degradation I	140.9	168.7	↑	3.15	1.22	6.1E-03
	PWY-7357: thiamine phosphate formation from pyrithiamine and oxythiamine	283.5	333.4	↑	2.38	1.38	1.2E-03
	COMPLETE-ARO-PWY: superpathway of aromatic amino acid biosynthesis	435.5	470.6	↑	1.89	1.22	6.4E-03
	*PWY-6731: starch degradation III	24.0	42.9	↑	1.83	1.01	5.8E-03
	PWY-622: starch biosynthesis	34.1	61.1	↑	1.81	1.14	6.0E-03
	THISYNARA-PWY: superpathway of thiamine diphosphate biosynthesis III	214.5	242.2	↑	0.76	1.14	0.014
	ANAGLYCOLYSIS-PWY: glycolysis III (from glucose)	392.8	427.7	↑	0.51	1.27	4.6E-04
PWY-7115: C4 photosynthetic carbon assimilation cycle, NAD-ME type	43.4	63.2	↑	0.12	1.01	0.021	

709 *Also significant in the same comparison in the children; ↑ higher with high disadvantage / psych, ↓ higher with low disadvantage / psych

710

711 **Table 3.** Metabolic pathways differential abundance in the children, based on
 712 comparisons of high-vs-low SD scores and high-vs-low Machine learning algorithm can
 713 correctly classify children as low and high mother SD 71.8% of the time ($P = 8.6 \times 10^{-4}$
 714 compared to random assignment; FDR-corrected binomial distribution test). Average
 715 abundance and association (high or low) are shown for the pathways predictive value in
 716 the top-25 RF model (ranked by mean decrease in accuracy of the RF model; MDA), and
 717 with LEfSe effect size ≥ 1 . The $-\log$ of the Kruskal-Wallis test P values from LEfSe is also
 718 shown.

Comparison	MetaCyc pathway ID	Average abundance (CPM)			Random Forest (top 25) MDA (%)	LEfSe results	
		Low Disadv.	High Disadv.	Direction		Effect size	Kruskal wallis P value
Child – Dis-advantage	PWY-5505: L-glutamate and L-glutamine biosynthesis	9.3	38.7	↑	7.91	1.20	7.9E-07
	PWY-7210: pyrimidine deoxyribonucleotides biosynthesis from CTP	29.2	78.8	↑	6.35	1.42	4.0E-04
	*PWY-6549: L-glutamine biosynthesis III	33.9	58.5	↑	6.30	1.12	6.5E-05
	GOLPDLCAT-PWY: superpathway of glycerol degradation to 1,3-propanediol	35.1	58.2	↑	4.90	1.00	1.4E-03
	TEICHOICACID-PWY: poly(glycerol phosphate) wall teichoic acid biosynthesis	21.8	48.9	↑	4.51	1.15	2.1E-04
	PWY-6897: thiamine diphosphate salvage II	167.3	223.2	↑	3.19	1.43	9.9E-05
	PWY-6700: queuosine biosynthesis I (de novo)	207.5	292.3	↑	2.70	1.61	5.4E-04
	PWY-6470: peptidoglycan biosynthesis V (β-lactam resistance)	26.6	74.8	↑	2.59	1.34	1.3E-04
	PWY-6124: inosine-5'-phosphate biosynthesis II	275.7	341.1	↑	2.47	1.54	3.8E-04
	PWY-1042: glycolysis IV	396.4	483.2	↑	1.68	1.60	1.3E-03
	PWY0-1296: purine ribonucleosides degradation	205.7	255.8	↑	1.18	1.39	0.032
	PWY0-1479: tRNA processing	187.7	132.5	↓	6.01	1.46	1.6E-03
	Child - Psych	*PWY-6549: L-glutamine biosynthesis III	29.2	56.9	↑	6.72	1.15
PWY-4981: L-proline biosynthesis II (from arginine)		68.9	115.6	↑	4.54	1.42	0.010
PWY-5505: L-glutamate and L-glutamine biosynthesis		13.5	37.6	↑	4.00	1.13	1.6E-04
*PWY-6731: starch degradation III		59.1	86.1	↑	3.53	1.16	0.034
ANAEROFRUCAT-PWY: homolactic fermentation		281.5	331.0	↑	3.00	1.39	8.9E-03
TRPSYN-PWY: L-tryptophan biosynthesis		266.0	321.2	↑	2.26	1.43	5.1E-03
PWY-241: C4 photosynthetic carbon assimilation cycle, NADP-ME type		83.4	119.1	↑	1.72	1.26	8.0E-03
FUC-RHAMCAT-PWY: superpathway of fucose and rhamnose degradation	76.4	53.8	↓	5.18	1.08	0.021	

719 *Also significant in the same comparison in the mothers; ↑ higher with high disadvantage / psych, ↓ higher with low disadvantage / psych

720

721

722 **Table 4.** Random forest (RF) machine learning predictive accuracy for high-vs-low
 723 inflammatory markers based on GM taxonomic and pathway profiles. Prediction accuracy
 724 was consistently greater for IL-6 than for the other inflammatory markers. Bolded values
 725 correspond to comparisons for which $P < 0.005$ (after FDR correction).

		Prediction accuracy				FDR-adjusted P value for prediction accuracy			
		IL-6	IL-8	IL-10	TNF α	IL-6	IL-8	IL-10	TNF α
Mothers	Genomes	75.6%	64.0%	70.6%	74.1%	6.9E-04	0.039	2.8E-03	2.8E-03
	Pathways	72.1%	62.0%	68.6%	61.8%	6.9E-04	0.067	5.6E-03	0.18
Children	Genomes	77.8%	76.0%	74.5%	75.0%	6.9E-04	6.9E-04	6.9E-04	2.8E-03
	Pathways	75.6%	66.0%	66.7%	56.4%	1.8E-03	0.02	0.01	0.45

726

727

728 **Table 5.** MetaCyc pathways differential abundance in the mothers and children, based
 729 on comparisons of high-vs-low IL-6 abundance. Based on MGS HUMAnN3 MetaCyc
 730 pathway abundance, RF can successfully classify mothers as low and high IL-6 73.3% of
 731 the time ($P = 6.9 \times 10^{-4}$ compared to random assignment; FDR-corrected binomial
 732 distribution test). Average abundance and association (high or low) are shown for the
 733 pathways predictive value in the top-25 RF model (ranked by mean decrease in accuracy
 734 of the RF model; MDA), and with LEfSe effect size ≥ 1 . The -log of the Kruskal-Wallis test
 735 P values from LEfSe is also shown.

Comparison	MetaCyc pathway ID	Average abundance (CPM)			Random Forest (top 25) MDA (%)	LEfSe results	
		Low Disadv.	High Disadv.	Direction		Effect size	Kruskal wallis P value
Mother - IL-6	PWY-5104: L-isoleucine biosynthesis IV	83.3	115.6	↑	5.21	1.36	1.1E-02
	PWY3O-355: stearate biosynthesis III (fungi)	37.3	55.8	↑	4.58	1.20	3.5E-02
	PWY-5505: L-glutamate and L-glutamine biosynthesis	75.3	90.7	↑	4.54	1.13	3.3E-02
	COBALSYN-PWY: superpathway of adenosylcobalamin salvage from cobinamide I	205.8	231.9	↑	2.46	1.18	2.5E-02
Child - IL-6	PWY-7237: myo-, chiro- and scyllo-inositol degradation	152.9	286.4	↑	6.23	1.81	3.6E-04
	PWY-6549: L-glutamine biosynthesis III	34.5	71.9	↑	2.96	1.26	3.3E-03
	PWY0-1586: peptidoglycan maturation (meso-diaminopimelate containing)	369.8	517.5	↑	2.41	1.84	1.2E-03
	COBALSYN-PWY: superpathway of adenosylcobalamin salvage from cobinamide I	112.5	168.0	↑	1.32	1.48	4.5E-03
	PWY-6897: thiamine diphosphate salvage II	177.0	222.3	↑	0.19	1.38	0.003
	PWY-7328: superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis	208.8	149.3	↓	5.71	1.50	0.031
	GLUCOSE1PMETAB-PWY: glucose and glucose-1-phosphate degradation	375.7	237.1	↓	5.62	1.87	1.6E-02
	GLYCOCAT-PWY: glycogen degradation I	487.9	327.3	↓	4.84	1.91	1.5E-02

736 ↑ higher with high IL-6, ↓ higher with low IL-6

737

738 **Acknowledgments**

739 Funding, Washington University in St. Louis' GTAC@MGI for library construction and
740 sequencing, NIMH grant RO1 MH113883, (BBW, BAR, IMN, PPT, PJM, SKE, JLL, CER,
741 TAS, CDS, DMB, GEM, EC, JM, MM) March of Dimes (SKE), Children's Discovery
742 Institute II MD-II-2015-489 (BBW, IMN), Biobank Core P30DK052574 (PIT).

743

744 **Author Contributions**

745 Conceived and designed the study: BBW, MM JL, DB, CER CDS

746 Assembled the cohort, collected specimens: IMN, LL, SKE

747 Biological and clinical data database maintenance: IMN, REB, JDW, CH-M

748 Sample preparation and extraction of DNA: IMN, REB, JDW, CH-M

749 Performed data analysis: BAR, MM, JM, PJM, GEM,EC

750 Interpreted the data: BAR, MM, BBW, JM PPT, IMN

751 Wrote the paper: BAR, MM, BBW

752 All authors approve the manuscript for publication.

753

754 **Competing Interest**

755 The authors have no competing interests to disclose.

756

757 **Additional information**

758 We thank the families involved in the study, the MARCH of Dime Premature Research

759 Center at Washington University, and the GTAC@MGI for the sequence data generation.

760

761 **Supplementary Figures**

762 **Supplementary Figure S1:** The relative abundance of *Bifidobacterium* species identified
763 in all mothers and children in the high-SD vs low-SD comparisons.

764

765 **Supplementary Figure S2:** The relative abundance of *Blautia* species identified in all
766 mothers and children in the high-SD vs low-SD comparisons.

767

768 **Supplementary Figure S3:** Based on WMS genome profiles, RF can successfully
769 classify mothers as low and high IL-6 abundance 75.6% of the time ($P = 2.2 \times 10^{-4}$
770 compared to random assignment; FDR-corrected binomial distribution test). Taxonomy
771 and relative abundance per sample for the genomes with the greatest predictive value in
772 the top-25 RF model are shown (ranked by mean decrease in accuracy of the RF model;
773 MDA). Also displayed are -Log of the Kruskal-Wallis test P values from LEfSe (no value
774 shown if the effect size was < 2) and the overall abundance of the taxa when present.

775

776 **Supplementary Figure S4:** Comparison of Social Disadvantage scores and
777 Psychological Stressors scores to maternal third trimester inflammatory marker serum
778 concentrations. Only IL-8 and PS scores correlated significantly.

779

780 **Supplementary Tables**

781 **Supplementary Table S1:** Complete patient characteristics at study entry for each of the
782 primary comparisons of interest. "Low" and "High" Disadvantage and Psych scores are
783 separated according to the distribution of the metadata, as shown in Figure 1.

784 **Supplementary Table S2:** Database of sample data, including metadata, indications of
785 sample groups for each comparison, relative 16S ASV abundance, relative MGS genome
786 abundance and relative MGS pathway abundance values.

787 **Supplementary Table S3:** Full ASV sequences for each unique ASV identifier from Table
788 S2.

789 **Supplementary Table S4:** Differential abundance statistics for each UHGG genome in
790 each comparison.

791 **Supplementary Table S5:** Differential abundance statistics for each MetaCyc pathway
792 in each comparison.

793

794 **References**

- 795 1. The L. Taking urgent action on health inequities. *Lancet*. 2020;395(10225):659. doi:
796 10.1016/S0140-6736(20)30455-4. PubMed PMID: 32113488.
- 797 2. Woolf SH, Schoomaker H. Life Expectancy and Mortality Rates in the United States, 1959-
798 2017. *JAMA*. 2019;322(20):1996-2016. doi: 10.1001/jama.2019.16932. PubMed PMID:
799 31769830; PMCID: PMC7146991.
- 800 3. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease
801 in England and Wales. *Lancet*. 1986;1(8489):1077-81. doi: 10.1016/s0140-6736(86)91340-1.
802 PubMed PMID: 2871345.
- 803 4. Nobile S, Di Sipio Morgia C, Vento G. Perinatal Origins of Adult Disease and Opportunities
804 for Health Promotion: A Narrative Review. *J Pers Med*. 2022;12(2). Epub 20220125. doi:
805 10.3390/jpm12020157. PubMed PMID: 35207646; PMCID: PMC8877993.
- 806 5. Simeoni U, Armengaud JB, Siddeek B, Tolsa JF. Perinatal Origins of Adult Disease.
807 *Neonatology*. 2018;113(4):393-9. Epub 20180531. doi: 10.1159/000487618. PubMed PMID:
808 29852488.
- 809 6. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy
810 DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando
811 TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM. Chronic inflammation in the etiology of
812 disease across the life span. *Nat Med*. 2019;25(12):1822-32. Epub 20191205. doi:
813 10.1038/s41591-019-0675-0. PubMed PMID: 31806905; PMCID: PMC7147972.
- 814 7. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev*
815 *Microbiol*. 2021;19(1):55-71. Epub 20200904. doi: 10.1038/s41579-020-0433-9. PubMed PMID:
816 32887946.
- 817 8. Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, Gustafsson A, Bernhardsson
818 AK, Zhang C, Bohlin K, Brodin P. Stereotypic Immune System Development in Newborn Children.
819 *Cell*. 2018;174(5):1277-92 e14. doi: 10.1016/j.cell.2018.06.045. PubMed PMID: 30142345;
820 PMCID: PMC6108833.

- 821 9. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van
822 Ree R, Stobberingh EE. Gut microbiota composition and development of atopic manifestations in
823 infancy: the KOALA Birth Cohort Study. *Gut*. 2007;56(5):661-7. Epub 20061017. doi:
824 10.1136/gut.2006.100164. PubMed PMID: 17047098; PMCID: PMC1942165.
- 825 10. Mbakwa CA, Hermes GDA, Penders J, Savelkoul PHM, Thijs C, Dagnelie PC, Mommers
826 M, Zoetendal EG, Smidt H, Arts ICW. Gut Microbiota and Body Weight in School-Aged Children:
827 The KOALA Birth Cohort Study. *Obesity (Silver Spring)*. 2018;26(11):1767-76. Epub 20181008.
828 doi: 10.1002/oby.22320. PubMed PMID: 30296366; PMCID: PMC6646907.
- 829 11. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen
830 ZS. Microbiota in health and diseases. *Signal Transduct Target Ther*. 2022;7(1):135. Epub
831 20220423. doi: 10.1038/s41392-022-00974-4. PubMed PMID: 35461318; PMCID: PMC9034083.
- 832 12. Karl JP, Hatch AM, Arcidiacono SM, Pearce SC, Pantoja-Feliciano IG, Doherty LA, Soares
833 JW. Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota. *Front
834 Microbiol*. 2018;9:2013. Epub 20180911. doi: 10.3389/fmicb.2018.02013. PubMed PMID:
835 30258412; PMCID: PMC6143810.
- 836 13. Amato KR, Arrieta MC, Azad MB, Bailey MT, Broussard JL, Bruggeling CE, Claud EC,
837 Costello EK, Davenport ER, Dutilh BE, Swain Ewald HA, Ewald P, Hanlon EC, Julion W,
838 Keshavarzian A, Maurice CF, Miller GE, Preidis GA, Segurel L, Singer B, Subramanian S, Zhao
839 L, Kuzawa CW. The human gut microbiome and health inequities. *Proc Natl Acad Sci U S A*.
840 2021;118(25). doi: 10.1073/pnas.2017947118. PubMed PMID: 34161260; PMCID:
841 PMC8237592.
- 842 14. Herd P, Palloni A, Rey F, Dowd JB. Social and population health science approaches to
843 understand the human microbiome. *Nat Hum Behav*. 2018;2(11):808-15. Epub 20181022. doi:
844 10.1038/s41562-018-0452-y. PubMed PMID: 31457107; PMCID: PMC6711373.
- 845 15. Bowyer RCE, Jackson MA, Le Roy CI, Ni Lochlainn M, Spector TD, Dowd JB, Steves CJ.
846 Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study. *Microorganisms*.
847 2019;7(1). Epub 20190111. doi: 10.3390/microorganisms7010017. PubMed PMID: 30641975;
848 PMCID: PMC6351927.
- 849 16. Miller GE, Engen PA, Gillevet PM, Shaikh M, Sikaroodi M, Forsyth CB, Mutlu E,
850 Keshavarzian A. Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity
851 of the Colonic Microbiota in Healthy Adults. *PLoS One*. 2016;11(2):e0148952. Epub 20160209.
852 doi: 10.1371/journal.pone.0148952. PubMed PMID: 26859894; PMCID: PMC4747579.
- 853 17. He Y, Wu W, Wu S, Zheng HM, Li P, Sheng HF, Chen MX, Chen ZH, Ji GY, Zheng ZD,
854 Mujagond P, Chen XJ, Rong ZH, Chen P, Lyu LY, Wang X, Xu JB, Wu CB, Yu N, Xu YJ, Yin J,
855 Raes J, Ma WJ, Zhou HW. Linking gut microbiota, metabolic syndrome and economic status
856 based on a population-level analysis. *Microbiome*. 2018;6(1):172. Epub 20180924. doi:
857 10.1186/s40168-018-0557-6. PubMed PMID: 30249275; PMCID: PMC6154942.
- 858 18. Zijlmans MA, Korpela K, Riksen-Walraven JM, de Vos WM, de Weerth C. Maternal
859 prenatal stress is associated with the infant intestinal microbiota. *Psychoneuroendocrinology*.
860 2015;53:233-45. Epub 20150119. doi: 10.1016/j.psyneuen.2015.01.006. PubMed PMID:
861 25638481.
- 862 19. Aatsinki AK, Kesitalo A, Laitinen V, Munukka E, Uusitupa HM, Lahti L, Kortelainen S,
863 Mustonen P, Rodrigues AJ, Coimbra B, Huovinen P, Karlsson H, Karlsson L. Maternal prenatal
864 psychological distress and hair cortisol levels associate with infant fecal microbiota composition
865 at 2.5 months of age. *Psychoneuroendocrinology*. 2020;119:104754. Epub 20200605. doi:
866 10.1016/j.psyneuen.2020.104754. PubMed PMID: 32531627.
- 867 20. Kang LJ, Vu KN, Koleva PT, Field CJ, Chow A, Azad MB, Becker AB, Mandhane PJ,
868 Moraes TJ, Sears MR, Lefebvre DL, Turvey SE, Subbarao P, Lou WYW, Scott JA, Kozyrskyj AL.
869 Maternal psychological distress before birth influences gut immunity in mid-infancy. *Clin Exp
870 Allergy*. 2020;50(2):178-88. Epub 20200115. doi: 10.1111/cea.13551. PubMed PMID: 31845414.

- 871 21. Hantsoo L, Jasarevic E, Criniti S, McGeehan B, Tanes C, Sammel MD, Elovitz MA,
872 Compher C, Wu G, Epperson CN. Childhood adversity impact on gut microbiota and inflammatory
873 response to stress during pregnancy. *Brain Behav Immun*. 2019;75:240-50. Epub 20181103. doi:
874 10.1016/j.bbi.2018.11.005. PubMed PMID: 30399404; PMCID: PMC6349044.
- 875 22. Hechler C, Borewicz K, Beijers R, Saccenti E, Riksen-Walraven M, Smidt H, de Weerth
876 C. Association between Psychosocial Stress and Fecal Microbiota in Pregnant Women. *Sci Rep*.
877 2019;9(1):4463. Epub 20190314. doi: 10.1038/s41598-019-40434-8. PubMed PMID: 30872645;
878 PMCID: PMC6418257.
- 879 23. Levin AM, Sitarik AR, Havstad SL, Fujimura KE, Wegienka G, Cassidy-Bushrow AE, Kim
880 H, Zoratti EM, Lukacs NW, Boushey HA, Ownby DR, Lynch SV, Johnson CC. Joint effects of
881 pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and
882 diversity. *Sci Rep*. 2016;6:31775. Epub 20160825. doi: 10.1038/srep31775. PubMed PMID:
883 27558272; PMCID: PMC4997337.
- 884 24. Jahnke JR, Roach J, Azcarate-Peril MA, Thompson AL. Maternal precarity and HPA axis
885 functioning shape infant gut microbiota and HPA axis development in humans. *PLoS One*.
886 2021;16(5):e0251782. Epub 20210520. doi: 10.1371/journal.pone.0251782. PubMed PMID:
887 34015045; PMCID: PMC8136730.
- 888 25. Lewis CR, Bonham KS, McCann SH, Volpe AR, D'Sa V, Naymik M, De Both MD,
889 Huentelman MJ, Lemery-Chalfant K, Highlander SK, Deoni SCL, Klepac-Ceraj V. Family SES Is
890 Associated with the Gut Microbiome in Infants and Children. *Microorganisms*. 2021;9(8). Epub
891 20210728. doi: 10.3390/microorganisms9081608. PubMed PMID: 34442687; PMCID:
892 PMC8398307.
- 893 26. Jain N. The early life education of the immune system: Moms, microbes and (missed)
894 opportunities. *Gut Microbes*. 2020;12(1):1824564. Epub 20201012. doi:
895 10.1080/19490976.2020.1824564. PubMed PMID: 33043833; PMCID: PMC7781677.
- 896 27. Cowan CSM, Dinan TG, Cryan JF. Annual Research Review: Critical windows - the
897 microbiota-gut-brain axis in neurocognitive development. *J Child Psychol Psychiatry*.
898 2020;61(3):353-71. Epub 20191126. doi: 10.1111/jcpp.13156. PubMed PMID: 31773737.
- 899 28. Laursen MF, Bahl MI, Licht TR. Settlers of our inner surface - factors shaping the gut
900 microbiota from birth to toddlerhood. *FEMS Microbiol Rev*. 2021;45(4). doi:
901 10.1093/femsre/fuab001. PubMed PMID: 33428723; PMCID: PMC8371275.
- 902 29. Luby JL, Barch DM, Warner B, Rogers C, Smyser CD, Triplett R, Arora J, Smyser T,
903 England SK, Slavich G, Stout M, Miller P. Modeling Prenatal Adversity/Advantage: Effects on
904 Birth Weight. *MedRxiv*. 2021. doi: <https://doi.org/10.1101/2021.12.16.21267938>.
- 905 30. Ridley M, Rao G, Schilbach F, Patel V. Poverty, depression, and anxiety: Causal evidence
906 and mechanisms. *Science*. 2020;370(6522). Epub 2020/12/12. doi: 10.1126/science.aay0214.
907 PubMed PMID: 33303583.
- 908 31. Ma J, Li Z, Zhang W, Zhang C, Zhang Y, Mei H, Zhuo N, Wang H, Wang L, Wu D.
909 Comparison of gut microbiota in exclusively breast-fed and formula-fed babies: a study of 91 term
910 infants. *Sci Rep*. 2020;10(1):15792. Epub 2020/09/27. doi: 10.1038/s41598-020-72635-x.
911 PubMed PMID: 32978424; PMCID: PMC7519658.
- 912 32. Almeida A, Nayfach S, Boland M, Strozzii F, Beracochea M, Shi ZJ, Pollard KS, Sakharova
913 E, Parks DH, Hugenholtz P, Segata N, Kyrpides NC, Finn RD. A unified catalog of 204,938
914 reference genomes from the human gut microbiome. *Nat Biotechnol*. 2021;39(1):105-14. Epub
915 2020/07/22. doi: 10.1038/s41587-020-0603-3. PubMed PMID: 32690973; PMCID: PMC7801254.
- 916 33. Olm MR, Crits-Christoph A, Bouma-Gregson K, Firek BA, Morowitz MJ, Banfield JF.
917 inStrain profiles population microdiversity from metagenomic data and sensitively detects shared
918 microbial strains. *Nat Biotechnol*. 2021;39(6):727-36. Epub 2021/01/20. doi: 10.1038/s41587-
919 020-00797-0. PubMed PMID: 33462508.
- 920 34. Wang S, Zeng S, Egan M, Cherry P, Strain C, Morais E, Boyaval P, Ryan CA, E MD, Ross
921 RP, Stanton C. Metagenomic analysis of mother-infant gut microbiome reveals global distinct and

- 922 shared microbial signatures. *Gut Microbes.* 2021;13(1):1-24. doi:
923 10.1080/19490976.2021.1911571. PubMed PMID: 33960282; PMCID: PMC8115609.
- 924 35. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, Tett A, Huttenhower
925 C, Segata N. MetaPhlan2 for enhanced metagenomic taxonomic profiling. *Nat Methods.*
926 2015;12(10):902-3. doi: 10.1038/nmeth.3589. PubMed PMID: 26418763.
- 927 36. Caspi R, Billington R, Keseler IM, Kothari A, Krummenacker M, Midford PE, Ong WK,
928 Paley S, Subhraveti P, Karp PD. The MetaCyc database of metabolic pathways and enzymes - a
929 2019 update. *Nucleic Acids Res.* 2020;48(D1):D445-D53. Epub 2019/10/06. doi:
930 10.1093/nar/gkz862. PubMed PMID: 31586394; PMCID: PMC6943030.
- 931 37. Franzosa EA, Mclver LJ, Rahnnavard G, Thompson LR, Schirmer M, Weingart G, Lipson
932 KS, Knight R, Caporaso JG, Segata N, Huttenhower C. Species-level functional profiling of
933 metagenomes and metatranscriptomes. *Nat Methods.* 2018;15(11):962-8. Epub 2018/11/01. doi:
934 10.1038/s41592-018-0176-y. PubMed PMID: 30377376; PMCID: PMC6235447.
- 935 38. Beghini F, Mclver LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A,
936 Manghi P, Scholz M, Thomas AM, Valles-Colomer M, Weingart G, Zhang Y, Zolfo M, Huttenhower
937 C, Franzosa EA, Segata N. Integrating taxonomic, functional, and strain-level profiling of diverse
938 microbial communities with bioBakery 3. *Elife.* 2021;10. Epub 2021/05/05. doi:
939 10.7554/eLife.65088. PubMed PMID: 33944776; PMCID: PMC8096432.
- 940 39. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods.*
941 2012;9(4):357-9. Epub 2012/03/06. doi: 10.1038/nmeth.1923. PubMed PMID: 22388286; PMCID:
942 PMC3322381.
- 943 40. Knights D, Costello EK, Knight R. Supervised classification of human microbiota. *FEMS*
944 *Microbiol Rev.* 2011;35(2):343-59. Epub 2010/11/03. doi: 10.1111/j.1574-6976.2010.00251.x.
945 PubMed PMID: 21039646.
- 946 41. Malan-Muller S, Valles-Colomer M, Foxx CL, Vieira-Silva S, van den Heuvel LL, Raes J,
947 Seedat S, Lowry CA, Hemmings SMJ. Exploring the relationship between the gut microbiome and
948 mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed
949 controls. *Eur Neuropsychopharmacol.* 2022;56:24-38. Epub 2021/12/16. doi:
950 10.1016/j.euroneuro.2021.11.009. PubMed PMID: 34923209.
- 951 42. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C.
952 Metagenomic biomarker discovery and explanation. *Genome Biol.* 2011;12(6):2011-12.
- 953 43. Sakamoto M, Iino T, Yuki M, Ohkuma M. *Lawsonibacter asaccharolyticus* gen. nov., sp.
954 nov., a butyrate-producing bacterium isolated from human faeces. *Int J Syst Evol Microbiol.*
955 2018;68(6):2074-81. Epub 2018/05/10. doi: 10.1099/ijsem.0.002800. PubMed PMID: 29745868.
- 956 44. Sakamoto M, Ikeyama N, Yuki M, Ohkuma M. Draft Genome Sequence of *Lawsonibacter*
957 *asaccharolyticus* JCM 32166(T), a Butyrate-Producing Bacterium, Isolated from Human Feces.
958 *Genome Announc.* 2018;6(25). Epub 2018/06/21. doi: 10.1128/genomeA.00563-18. PubMed
959 PMID: 29930067; PMCID: PMC6013597.
- 960 45. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial
961 effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol.*
962 2011;17(12):1519-28. doi: 10.3748/wjg.v17.i12.1519
963 10.3748/wjg.v17.i12.1519. PubMed PMID: 21472114; PMCID: PMC3070119.
- 964 46. Uriot O, Denis S, Junjua M, Roussel Y, Dary-Mouro A, Blanquet-Diot S. *Streptococcus*
965 *thermophilus*: From yogurt starter to a new promising probiotic candidate? *Journal of Functional*
966 *Foods.* 2017;37:74-89. doi: <https://doi.org/10.1016/j.jff.2017.07.038>.
- 967 47. Arbolea S, Watkins C, Stanton C, Ross RP. Gut Bifidobacteria Populations in Human
968 Health and Aging. *Front Microbiol.* 2016;7:1204. Epub 2016/09/07. doi:
969 10.3389/fmicb.2016.01204. PubMed PMID: 27594848; PMCID: PMC4990546.
- 970 48. Gueimonde M, Ouwehand A, Huhtinen H, Salminen E, Salminen S. Qualitative and
971 quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with
972 colorectal cancer, diverticulitis and inflammatory bowel disease. *World J Gastroenterol.*

- 973 2007;13(29):3985-9. Epub 2007/08/01. doi: 10.3748/wjg.v13.i29.3985. PubMed PMID:
974 17663515; PMCID: PMC4171173.
- 975 49. Knudsen JK, Bundgaard-Nielsen C, Hjerrild S, Nielsen RE, Leutscher P, Sorensen S. Gut
976 microbiota variations in patients diagnosed with major depressive disorder-A systematic review.
977 *Brain Behav.* 2021;11(7):e02177. Epub 20210528. doi: 10.1002/brb3.2177. PubMed PMID:
978 34047485; PMCID: PMC8323045.
- 979 50. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social
980 stressor alters the structure of the intestinal microbiota: implications for stressor-induced
981 immunomodulation. *Brain Behav Immun.* 2011;25(3):397-407. Epub 20101030. doi:
982 10.1016/j.bbi.2010.10.023. PubMed PMID: 21040780; PMCID: PMC3039072.
- 983 51. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L, Ruan
984 B. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav*
985 *Immun.* 2015;48:186-94. Epub 20150413. doi: 10.1016/j.bbi.2015.03.016. PubMed PMID:
986 25882912.
- 987 52. Chung YE, Chen HC, Chou HL, Chen IM, Lee MS, Chuang LC, Liu YW, Lu ML, Chen CH,
988 Wu CS, Huang MC, Liao SC, Ni YH, Lai MS, Shih WL, Kuo PH. Exploration of microbiota targets
989 for major depressive disorder and mood related traits. *J Psychiatr Res.* 2019;111:74-82. Epub
990 20190119. doi: 10.1016/j.jpsychires.2019.01.016. PubMed PMID: 30685565.
- 991 53. Wang J, Chen WD, Wang YD. The Relationship Between Gut Microbiota and
992 Inflammatory Diseases: The Role of Macrophages. *Front Microbiol.* 2020;11:1065. Epub
993 2020/06/26. doi: 10.3389/fmicb.2020.01065. PubMed PMID: 32582063; PMCID: PMC7296120.
- 994 54. Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley
995 EM. *Bifidobacterium infantis* 35624 modulates host inflammatory processes beyond the gut. *Gut*
996 *Microbes.* 2013;4(4):325-39. Epub 2013/07/12. doi: 10.4161/gmic.25487. PubMed PMID:
997 23842110; PMCID: PMC3744517.
- 998 55. Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li Y, Xia Y, Xie
999 H, Zhong H, Khan MT, Zhang J, Li J, Xiao L, Al-Aama J, Zhang D, Lee YS, Kotowska D, Colding
1000 C, Tremaroli V, Yin Y, Bergman S, Xu X, Madsen L, Kristiansen K, Dahlgren J, Wang J. Dynamics
1001 and Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell Host Microbe.*
1002 2015;17(5):690-703. Epub 2015/05/15. doi: 10.1016/j.chom.2015.04.004. PubMed PMID:
1003 25974306.
- 1004 56. Hall AB, Yassour M, Sauk J, Garner A, Jiang X, Arthur T, Lagoudas GK, Vatanen T,
1005 Fornelos N, Wilson R, Bertha M, Cohen M, Garber J, Khalili H, Gevers D, Ananthakrishnan AN,
1006 Kugathasan S, Lander ES, Blainey P, Vlamakis H, Xavier RJ, Huttenhower C. A novel
1007 *Ruminococcus gnavus* clade enriched in inflammatory bowel disease patients. *Genome Med.*
1008 2017;9(1):103. Epub 2017/12/01. doi: 10.1186/s13073-017-0490-5. PubMed PMID: 29183332;
1009 PMCID: PMC5704459.
- 1010 57. Hiippala K, Kainulainen V, Kalliomaki M, Arkkila P, Satokari R. Mucosal Prevalence and
1011 Interactions with the Epithelium Indicate Commensalism of *Sutterella* spp. *Front Microbiol.*
1012 2016;7:1706. Epub 2016/11/12. doi: 10.3389/fmicb.2016.01706. PubMed PMID: 27833600;
1013 PMCID: PMC5080374.
- 1014 58. Pokusaeva K, Fitzgerald GF, van Sinderen D. Carbohydrate metabolism in *Bifidobacteria*.
1015 *Genes Nutr.* 2011;6(3):285-306. Epub 20110216. doi: 10.1007/s12263-010-0206-6. PubMed
1016 PMID: 21484167; PMCID: PMC3145055.
- 1017 59. Caputo M, Bona E, Leone I, Sama MT, Nuzzo A, Ferrero A, Aimaretti G, Marzullo P,
1018 Prodam F. Inositols and metabolic disorders: From farm to bedside. *J Tradit Complement Med.*
1019 2020;10(3):252-9. Epub 20200324. doi: 10.1016/j.jtcme.2020.03.005. PubMed PMID: 32670820;
1020 PMCID: PMC7340869.
- 1021 60. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS. Decreased
1022 prefrontal Myo-inositol in major depressive disorder. *Biol Psychiatry.* 2005;57(12):1526-34. doi:
1023 10.1016/j.biopsych.2005.02.027. PubMed PMID: 15953489.

- 1024 61. Nie X, Chen J, Ma X, Ni Y, Shen Y, Yu H, Panagiotou G, Bao Y. A metagenome-wide
1025 association study of gut microbiome and visceral fat accumulation. *Comput Struct Biotechnol J*.
1026 2020;18:2596-609. Epub 20200920. doi: 10.1016/j.csbj.2020.09.026. PubMed PMID: 33033580;
1027 PMCID: PMC7528071.
- 1028 62. Perna S, Alalwan TA, Alaali Z, Alnashaba T, Gasparri C, Infantino V, Hammad L, Riva A,
1029 Petrangolini G, Allegrini P, Rondanelli M. The Role of Glutamine in the Complex Interaction
1030 between Gut Microbiota and Health: A Narrative Review. *Int J Mol Sci*. 2019;20(20). Epub
1031 2019/10/28. doi: 10.3390/ijms20205232. PubMed PMID: 31652531; PMCID: PMC6834172.
- 1032 63. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal
1033 brain development through interleukin-6. *J Neurosci*. 2007;27(40):10695-702. Epub 2007/10/05.
1034 doi: 10.1523/JNEUROSCI.2178-07.2007. PubMed PMID: 17913903; PMCID: PMC2387067.
- 1035 64. Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffler CA, Littman DR, Huh JR. The
1036 maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. *Science*.
1037 2016;351(6276):933-9. Epub 20160128. doi: 10.1126/science.aad0314. PubMed PMID:
1038 26822608; PMCID: PMC4782964.
- 1039 65. Wu WL, Hsiao EY, Yan Z, Mazmanian SK, Patterson PH. The placental interleukin-6
1040 signaling controls fetal brain development and behavior. *Brain Behav Immun*. 2017;62:11-23.
1041 Epub 20161109. doi: 10.1016/j.bbi.2016.11.007. PubMed PMID: 27838335; PMCID:
1042 PMC5373986.
- 1043 66. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-
1044 phylogenetic characterization of microbial community imbalances in human inflammatory bowel
1045 diseases. *Proceedings of the National Academy of Sciences of the United States of America*.
1046 2007;104(34):13780-5. Epub 20070815. doi: 10.1073/pnas.0706625104. PubMed PMID:
1047 17699621; PMCID: PMC1959459.
- 1048 67. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, Ter Horst
1049 R, Jansen T, Jacobs L, Bonder MJ, Kurilshikov A, Fu J, Joosten LAB, Zhernakova A, Huttenhower
1050 C, Wijmenga C, Netea MG, Xavier RJ. Linking the Human Gut Microbiome to Inflammatory
1051 Cytokine Production Capacity. *Cell*. 2016;167(4):1125-36 e8. doi: 10.1016/j.cell.2016.10.020.
1052 PubMed PMID: 27814509; PMCID: PMC5131922.
- 1053 68. Shahini A, Shahini A. Role of interleukin-6-mediated inflammation in the pathogenesis of
1054 inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome.
1055 *J Cell Commun Signal*. 2022. Epub 20220916. doi: 10.1007/s12079-022-00695-x. PubMed PMID:
1056 36112307.
- 1057 69. Kanazawa A, Aida M, Yoshida Y, Kaga H, Katahira T, Suzuki L, Tamaki S, Sato J, Goto
1058 H, Azuma K, Shimizu T, Takahashi T, Yamashiro Y, Watada H. Effects of Synbiotic
1059 Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2
1060 Diabetes Mellitus: A Randomized Controlled Study. *Nutrients*. 2021;13(2). Epub 20210208. doi:
1061 10.3390/nu13020558. PubMed PMID: 33567701; PMCID: PMC7914668.
- 1062 70. Stout MJ, Chubiz J, Raghuraman N, Zhao P, Tuuli MG, Wang LV, Cahill AG, Cuculich PS,
1063 Wang Y, Jungheim ES, Herzog ED, Fay J, Schwartz AL, Macones GA, England SK. A
1064 multidisciplinary Prematurity Research Cohort Study. *PLoS One*. 2022;17(8):e0272155. Epub
1065 20220825. doi: 10.1371/journal.pone.0272155. PubMed PMID: 36006907; PMCID:
1066 PMC9409532.
- 1067 71. Cuschieri S. The STROBE guidelines. *Saudi J Anaesth*. 2019;13(Suppl 1):S31-S4. doi:
1068 10.4103/sja.SJA_543_18. PubMed PMID: 30930717; PMCID: PMC6398292.
- 1069 72. Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible -
1070 The Neighborhood Atlas. *N Engl J Med*. 2018;378(26):2456-8. Epub 2018/06/28. doi:
1071 10.1056/NEJMp1802313. PubMed PMID: 29949490; PMCID: PMC6051533.
- 1072 73. Institute NC. The Healthy Eating Index – Population Ratio Method Updated December 14,
1073 2021. Available from: <https://epi.grants.cancer.gov/hei/population-ratio-method.html>.


- 1074 74. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the
1075 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry*. 1987;150:782-6. doi:
1076 10.1192/bjp.150.6.782. PubMed PMID: 3651732.
- 1077 75. Cohen S, Kessler RC, Gordon LU. Perceived stress scale: Measuring stress: A guide for
1078 health and social scientists. Cohen S, Kessler RC, Gordon LU, editors. New York, NY, US: Oxford
1079 University Press; 1997. xii, 236-xii, p.
- 1080 76. Slavich GM, Shields GS. Assessing Lifetime Stress Exposure Using the Stress and
1081 Adversity Inventory for Adults (Adult STRAIN): An Overview and Initial Validation. *Psychosom*
1082 *Med*. 2018;80(1):17-27. doi: 10.1097/PSY.0000000000000534. PubMed PMID: 29016550;
1083 PMCID: PMC5757659.
- 1084 77. Lewis TT, Yang FM, Jacobs EA, Fitchett G. Racial/ethnic differences in responses to the
1085 everyday discrimination scale: a differential item functioning analysis. *Am J Epidemiol*.
1086 2012;175(5):391-401. Epub 20120203. doi: 10.1093/aje/kwr287. PubMed PMID: 22306556;
1087 PMCID: PMC3282874.
- 1088 78. Fein SB, Labiner-Wolfe J, Shealy KR, Li R, Chen J, Grummer-Strawn LM. Infant Feeding
1089 Practices Study II: study methods. *Pediatrics*. 2008;122 Suppl 2:S28-35. doi: 10.1542/peds.2008-
1090 1315c. PubMed PMID: 18829828.
- 1091 79. Planer JD, Peng Y, Kau AL, Blanton LV, Ndao IM, Tarr PI, Warner BB, Gordon JL.
1092 Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice.
1093 *Nature*. 2016;534(7606):263-6. Epub 20160525. doi: 10.1038/nature17940. PubMed PMID:
1094 27279225; PMCID: PMC4902178.
- 1095 80. Bennett WE, Jr., Gonzalez-Rivera R, Shaikh N, Magrini V, Boykin M, Warner BB, Hamvas
1096 A, Tarr PI. A method for isolating and analyzing human mRNA from newborn stool. *J Immunol*
1097 *Methods*. 2009;349(1-2):56-60. Epub 20090803. doi: 10.1016/j.jim.2009.07.013. PubMed PMID:
1098 19660464; PMCID: PMC2850193.
- 1099 81. Warner BB, Deych E, Zhou Y, Hall-Moore C, Weinstock GM, Sodergren E, Shaikh N,
1100 Hoffmann JA, Linneman LA, Hamvas A, Khanna G, Rouggy-Nickless LC, Ndao IM, Shands BA,
1101 Escobedo M, Sullivan JE, Radmacher PG, Shannon WD, Tarr PI. Gut bacteria dysbiosis and
1102 necrotising enterocolitis in very low birthweight infants: a prospective case-control study. *Lancet*.
1103 2016;387(10031):1928-36. Epub 20160309. doi: 10.1016/S0140-6736(16)00081-7. PubMed
1104 PMID: 26969089; PMCID: PMC5553277.
- 1105 82. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H,
1106 Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown
1107 CT, Callahan BJ, Caraballo-Rodriguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein
1108 PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz
1109 JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H,
1110 Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang KB, Keefe CR,
1111 Keim P, Kelley ST, Knights D, Koester I, Kosciulek T, Kreps J, Langille MGI, Lee J, Ley R, Liu
1112 YX, Lofffield E, Lozupone C, Maher M, Marotz C, Martin BD, McDonald D, McIver LJ, Melnik AV,
1113 Metcalf JL, Morgan SC, Morton JT, Naimey AT, Navas-Molina JA, Nothias LF, Orchanian SB,
1114 Pearson T, Peoples SL, Petras D, Preuss ML, Pruesse E, Rasmussen LB, Rivers A, Robeson
1115 MS, 2nd, Rosenthal P, Segata N, Shaffer M, Shiffer A, Sinha R, Song SJ, Spear JR, Swafford
1116 AD, Thompson LR, Torres PJ, Trinh P, Tripathi A, Turnbaugh PJ, UI-Hasan S, van der Hooft JJJ,
1117 Vargas F, Vazquez-Baeza Y, Vogtmann E, von Hippel M, Walters W, Wan Y, Wang M, Warren
1118 J, Weber KC, Williamson CHD, Willis AD, Xu ZZ, Zaneveld JR, Zhang Y, Zhu Q, Knight R,
1119 Caporaso JG. Reproducible, interactive, scalable and extensible microbiome data science using
1120 QIIME 2. *Nat Biotechnol*. 2019;37(8):852-7. Epub 2019/07/26. doi: 10.1038/s41587-019-0209-9.
1121 PubMed PMID: 31341288; PMCID: PMC7015180.
- 1122 83. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO.
1123 The SILVA ribosomal RNA gene database project: improved data processing and web-based
1124 tools. *Nucleic Acids Res*. 2013;41. doi: 10.1093/nar/gks1219.

- 1125 84. Balvociute M, Huson DH. SILVA, RDP, Greengenes, NCBI and OTT - how do these
1126 taxonomies compare? *BMC Genomics*. 2017;18(Suppl 2):114. doi: 10.1186/s12864-017-3501-4.
1127 PubMed PMID: 28361695; PMCID: PMC5374703.
- 1128 85. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
1129 data. *Bioinformatics*. 2014;30(15):2114-20. doi: 10.1093/bioinformatics/btu170. PubMed PMID:
1130 24695404; PMCID: PMC4103590.
- 1131 86. Martin FJ, Amode MR, Aneja A, Austine-Orimoloye O, Azov AG, Barnes I, Becker A,
1132 Bennett R, Berry A, Bhai J, Bhurji SK, Bignell A, Boddu S, Branco Lins PR, Brooks L, Ramaraju
1133 SB, Charkhchi M, Cockburn A, Da Rin Fiorretto L, Davidson C, Dodiya K, Donaldson S, El
1134 Houdaigui B, El Naboulsi T, Fatima R, Giron CG, Genez T, Ghattaoraya GS, Martinez JG, Guijarro
1135 C, Hardy M, Hollis Z, Hourlier T, Hunt T, Kay M, Kaykala V, Le T, Lemos D, Marques-Coelho D,
1136 Marugan JC, Merino GA, Mirabueno LP, Mushtaq A, Hossain SN, Ogeh DN, Sakthivel MP, Parker
1137 A, Perry M, Pilizota I, Prosovetskaia I, Perez-Silva JG, Salam AIA, Saraiva-Agostinho N,
1138 Schuilenburg H, Sheppard D, Sinha S, Sipos B, Stark W, Steed E, Sukumaran R, Sumathipala
1139 D, Suner MM, Surapaneni L, Sutinen K, Szpak M, Tricomi FF, Urbina-Gomez D, Veidenberg A,
1140 Walsh TA, Walts B, Wass E, Willhoft N, Allen J, Alvarez-Jarreta J, Chakiachvili M, Flint B, Giorgetti
1141 S, Haggerty L, Ilesley GR, Loveland JE, Moore B, Mudge JM, Tate J, Thybert D, Trevanion SJ,
1142 Winterbottom A, Frankish A, Hunt SE, Ruffier M, Cunningham F, Dyer S, Finn RD, Howe KL,
1143 Harrison PW, Yates AD, Flicek P. Ensembl 2023. *Nucleic Acids Res*. 2022. Epub 20221101. doi:
1144 10.1093/nar/gkac958. PubMed PMID: 36318249.
- 1145 87. Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH, UniProt C. UniRef clusters: a
1146 comprehensive and scalable alternative for improving sequence similarity searches.
1147 *Bioinformatics*. 2015;31(6):926-32. Epub 2014/11/16. doi: 10.1093/bioinformatics/btu739.
1148 PubMed PMID: 25398609; PMCID: PMC4375400.
- 1149 88. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara R, Simpson GL,
1150 Solymos P, Stevens M, Wagner H. *vegan: Community Ecology Package*. R package version 2.0-
1151 10. 2013. There is no corresponding record for this reference. 2015.
- 1152 89. Mason SJ, Graham NE. Areas beneath the relative operating characteristics (ROC) and
1153 relative operating levels (ROL) curves: Statistical significance and interpretation. *Quarterly
1154 Journal of the Royal Meteorological Society*. 2002;128(584):2145-66. doi:
1155 <https://doi.org/10.1256/003590002320603584>.
- 1156 90. Kleine Bardenhorst S, Berger T, Klawonn F, Vital M, Karch A, Rubsamen N. Data Analysis
1157 Strategies for Microbiome Studies in Human Populations-a Systematic Review of Current
1158 Practice. *mSystems*. 2021;6(1). Epub 20210223. doi: 10.1128/mSystems.01154-20. PubMed
1159 PMID: 33622856; PMCID: PMC8573962.
- 1160

1161


1162 **Figures**

1163 **Figure 1.**



1164

1165 **Figure 2:**




1166

1167

1168


1169 **Figure 3**



1170

1171


1172 **Figure 4**



1173


1174

1175 **Figure 5.**



1176


1177 **Figure 6.**



1178

1179

1180 **Figure 7.**




1181

1182

1183 **Figure 8.**


Child
IL-6 abundance



1184

1185

1186 **Supplementary Figure S1**




1187

1188

1189

1190

1202 **Supplementary Figure S3**





1203

1204

1205

1206 **Supplementary Figure S4**



1207